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Ovarian cancer is the most fatal cancer of the female reproductive system.
High-grade serous ovarian cancer (HGSOC) represent the majority of ovarian can-
cers and accounts for the largest proportion of deaths from the disease. From a
clinical perspective, the complex, heterogeneous behaviors of this women’s cancer
pose questions that cannot always be answered with contemporary clinical and ex-
perimental tools.
Studying the growth, progression, and dynamic response to treatment of ovar-
ian cancers in an integrated systems biology/mathematical framework offers an in-
novative tool at the disposal of the oncological community to further exploit read-
ily available clinical data and generate novel testable hypotheses. Developing novel
physiologically structured mathematical models to study the heterogeneous behavior
of this malignancy would help us to better understand patient therapeutic responses
and devise novel combination therapies.
As a first step, we developed a mathematical model for a quantitative ex-
planation why transvaginal ultrasound-based (TVU) screening fails to improve low-
volume detectability and overall survival (OS) of HGSOC. This mathematical model
can accurately estimate the efficacy of screening for this cancer subtype. The model
also explains the observed heterogeneity in cancer progression and duration of the
pre-diagnosis stage. Our mathematical model is consistent with recent case reports
and prospective TVU screening population studies, and provides support to the
empirical recommendation against frequent HGSOC screening.
At the cell population level, we have quantitatively investigated the role of
cell heterogeneity emerging from variations in cell-cycle parameters and cell-death.
Many commonly used chemotherapeutic agents in treating ovarian cancers target
only dividing cancer cells.
We recently demonstrated in a mathematical model, calibrated against pub-
lished in vitro cell culture data, that resistance to chemotherapeutic treatment may
arise from a dynamic, oscillatory balance between the dividing and non-dividing
cancer cells, which is conserved through time despite high long-term drug dosages.
At the single cell level, we developed a mathematical model to explain the
emerging heterogeneity in individual cancer cell responses to drugs targeting the
cell-cycle, which have a broad spectrum of anti-tumor activity in ovarian cancers.
This emerging heterogeneity remains a poorly understood mechanism that plays a
significant role in mediating drug response, and predicts the existence of an intrinsic
resistance mechanism to drug therapy.
The model incorporates an intrinsic form of heterogeneity via the duration of
time single cells spend in mitosis. It uses published single cell in vitro experimental
data for calibration. Herein, the goal is to better understand why, within a distinct
cell line, cells treated with identical drugs exhibit a considerable degree of hetero-
geneity in response to prolonged drug exposure. The model can serve as a basis for
future studies of the heterogeneity observed in vitro of more complex responses to
anti-mitotic drugs of different cell lines.
Studying the natural history, growth, and progression of ovarian cancers in an
integrated systems biology/mathematical framework represents a complementary
tool that can be used to provide valuable insights into the treatment of HGSOC.
My work focuses on developing and applying quantitative, integrated math-
ematical modeling frameworks to pre-clinical and clinical data, in order to better
understand ovarian cancer dynamics and develop new therapeutics.
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Chapter 1: Introduction
The goal of this dissertation is to develop and apply mathematical models to
study ovarian cancer. It takes an interdisciplinary approach, combining modeling
with experimental data, i.e., in vitro or in vivo data in order to investigate diverse
aspects of ovarian cancer growth dynamics, detection and therapeutic administra-
tion. The clinical background presented in this chapter constitutes the motivation
and foundation of the models subsequently presented.
1.1 Motivation
Women constitute the majority of the aging United States (US) population,
as, on average, they outlive men by 5 years [1]. According to the US Bureau of
the Census in 2010, the life expectancy of a female at birth was 81.1 years versus
76.2 years for a male. In this latest census, women accounted for about 60% of the
population aged 70 years or older.
Based on these demographic data, the computed ratio of number of post-
menopausal women to women of reproductive age was 2:3. This has substantial
implications on existing clinical practices, since an increased proportion of aging
women is associated with new disease patterns, such as differential incidence or
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prevalence rates [2, 3].
Ovarian cancer is a relatively rare women’s cancer, representing 1.3% of all
new cancer cases in US women [4]. However, it is the most fatal gynecologic cancer
type, with an ≈ 46.5% five-year overall survival rate [4]. Ovarian cancer is most
frequently diagnosed among women aged 55-64, with a median age of 63 years [4].
From a clinical perspective, the complex, heterogeneous behaviors of this sub-
set of women’s cancers pose questions that cannot always be exclusively and fea-
sibly answered with contemporary clinical and experimental tools. Studying the
origins, growth, progression, and dynamic response to treatment ovarian cancers in
an integrated systems biology/mathematical framework offers an innovative tool at
the disposal of the oncological community to further exploit readily available clin-
ical data, generate novel testable hypotheses or re-interpret existing experimental
data [2].
My dissertation research involves developing novel physiologically structured
mathematical models to study the heterogeneity in ovarian cancer initiation, pro-
gression and therapeutic responses.
1.2 Introduction to Human Ovarian Cancers
By the end of 2017, it is estimated that 22,440 new cases of ovarian cancer
with an estimated 14,080 deaths related to this disease will occur in the US, for
a computed 2:3 death to incidence ratio [4]. The high mortality rate following
diagnosis has been partly attributed to the approximately two thirds of patients
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presenting with advanced stage, when recurrence is common and ultimately leads
to the incurable disease.
The absence of accurate early detection screening methods poses additional
difficulties in reducing ovarian cancer mortality levels [5]. Several studies suggest
the usefulness of a symptom index tool to identify women who may have ovarian
cancer; this includes new (within 1 year) and persistent (more than 12x/month)
pelvic/abdominal pain, abdominal size/bloating, difficulty eating/feeling full, and
urinary urgency/frequency [6, 7], which should trigger evaluation by a gynecologic
oncologist. Surgical debulking is an integral part of the management of ovarian
cancer patients. The extent and quality of the debulking has important prognostic
value.
1.3 The Target Organ(s)
It is becoming increasingly recognized that ovarian cancers do not constitute
a single disease, but rather a family of non-uterine tubo-ovarian cancers (see Figure
2 in [2]).
Ovarian tumors may develop from epithelial, stromal or germ cells [8]. About
10-15% of all ovarian malignant tumors are non-epithelial in origin, are often found
at an early stage, and generally have a good prognosis [9]. Epithelial ovarian cancers
constitute about 85 - 90% of all ovarian cancer cases, with a subset of these epithelial
ovarian cancers, high-grade serous ovarian cancers (HGSOCs), representing nearly
70% of all ovarian cancer cases.
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HGSOC is considered to be an aggressive histological subgroup of the ovarian
malignancies [10]. Although the 5-year survival rate for stage I ovarian cancer is
greater than 80% [11], stage I diagnoses represent the exception rather than the
rule [4]. Most patients present with stage III/IV tumors, for which the 5-year
survival rate is less than 30% [4].
One of the obstacles to the detection of early-stage HGSOC has been the
poor understanding of its histopathogenesis. It was initially thought that epithelial
ovarian tumors originate from the ovarian surface epithelium, a single cell layer
covering the ovaries, coming from the coelomic epithelium [12,13].
Recent data suggest secretory cells inside the distal Fallopian tubes give rise to
the earliest precursor lesions in a proportion of HGSOC cases [12–15]. This finding
was first reported in women with germline BRCA1 and BRCA2 mutations undergo-
ing a prophylactic bilateral risk-reducing salpingo-oophorectomy procedure [16–18].
For the general-risk population however, it remains unclear whether diagnosed ovar-
ian tumors commonly arise with apparently Fallopian tube involvement, or consti-
tute truly ovarian-derived diseases.
1.4 Prophylactic and Early Detection Strategies
Any proposed screening strategy should be highly sensitive and specific to
detecting truly malignant ovarian cancer cases. Transvaginal ultrasound (TVU),
serum biomarkers (e.g., CA125, HE4) testing, pelvic examinations or simultaneous
TVU and CA125 testing have been examined as non-invasive tools for detecting
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early stage ovarian cancer in general-risk women.
However, recent evidence suggests that annual screening with TVU and serum
biomarkers does not reduce mortality [19]. Furthermore, high false positive rates
leading to intervention are associated with potential harm, such as unnecessary
surgical intervention and related complications.
The lack of utility of such screening tools is possibly due to the absence of
adequate TVU sensitivity in detecting small increases in tumor volume and dis-
tinguishing between malignant and benign cases [20]. Furthermore, the addition of
serum biomarkers testing (e.g., CA125 levels) does not improve early-stage detection
levels either [21, 22].
The largest ever ovarian cancer screening study of 202,638 general-risk women
demonstrated that multimodal screening including serial TVU and CA125 level
testing yielded a 15% mortality reduction rate compared with a 0% no screening
or 11% unimodal TVU-based screening cohort mortality reduction rate over 0-14
follow-up years [19,23].
However, this study also showed increased CA125 levels can be detected in
benign conditions, rendering it inadequate for use in screening asymptomatic women
for early-stage ovarian cancer. The lack of adequate early-detection tools might also
be explained by the fact that any epithelial ovarian cancers diagnosed in stage I
might be fundamentally different from those diagnosed in advanced stages, which
are preponderantly high and not low-grade cases [24,25].
United States Preventive Services and Task Force (USPSTF) has recently re-
confirmed their previous recommendation against screening in asymptomatic women
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without known genetic risk for ovarian cancer [26]; existing screening methods are
either not recommended as uni- or multimodal prognostic markers for low HGSOC
volume detection [27–29], or have not been shown to confer a mortality benefit in
general-risk women [30]. High-genetic risk women should be considered for genetic
counseling [31] and offered the option to undergo regular monitoring via a combi-
nation of TVU examinations and CA125 tests.
Many high-genetic risk women voluntarily choose to undergo various risk-
reducing gynecologic surgeries, such as prophylactic oophorectomies, bilateral salpingo-
oophorectomies or hysterectomies [32–35], which have been proven to reduce mor-
tality from both breast [13, 36–38] and ovarian cancer [37, 38]. Collectively, the
question of whether ovarian cancer is a valid target for routine screening in general-
or high genetic-risk women remains highly controversial [28,39,40].
1.5 Current Treatment Strategies
Standard treatments for ovarian cancers include debulking surgery, (neo)adjuvant
platinum-based combination chemotherapy, such as cisplatin or carboplatin, and a
taxane such as paclitaxel or docetaxel [41]. In addition to systemic chemotherapy,
targeted therapies such as small molecule tyrosine kinase inhibitors are also used.
For example, platinum-resistant recurrent ovarian cancers have been shown to re-
spond to angiogenesis inhibitors (e.g., bevacizumab) in combination with chemother-
apy, [42, 43].
Additionally, poly ADP-ribose polymerase (PARP) inhibitors have been used
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in clinical trial settings and the PARP inhibitor (PARPi) olaparib (Lynparza) was
recently approved by the US Food and Drug Administration (USFDA) as a therapy
for germline BRCA-mutations associated recurrent ovarian cancer [44,45].
1.6 Drug Resistance: Implications for Predicting Recurrence
Initial response rates to current standard treatments for ovarian cancer pa-
tients are high (70%-80%), but the majority of women with advanced disease re-
lapse with within two years [46]. Recurrent ovarian cancer is not curable, and most
women eventually develop a platinum-resistant disease.
Several mechanisms of cellular resistance to platinum compounds or PARPis
have been described [47], such as intracellular cisplatin inactivation via augmented
glutathione synthesis [48,49], or reduced intracellular drug concentration via overex-
pression of MDR1 protein acting as a drug efflux transporter [50]. Another possible
mechanism of platinum resistance is the development of secondary mutations restor-
ing functions of BRCA and other proteins of homologous recombination repair (HR)
in BRCA-mutated ovarian cancers.
However, BRCA restored functionality does not explain all cases of cisplatin
resistance in these patients [51–53], since not all platinum-resistant recurrent ovarian
carcinomas exhibit detectable secondary mutations.
Norquistet al. showed only 12 of 26 (46%) platinum-resistant recurrent cases
had detectable secondary mutations restoring BRCA function [54]. Further pre-
clinical and clinical investigations of mechanisms of platinum or PARPi resistance
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are thus needed.
Larger-scale prospective and retrospective cohort studies are warranted in or-
der to better examine therapy response heterogeneity and adaptability of the ovarian
cancer genome under the selective pressure of cytotoxic therapies [55–57].
1.7 Outline of Thesis
The remainder of this thesis is organized as follows. In Chapter 2, we review
and provide a detailed description of the existing mathematical models aimed at
describing various aspects of ovarian cancer’s natural history and progression. This
review was published in [2]. We then focus on a mathematical study of ovarian
cancer initiation, progression, and detection in silico in Chapter 3. These results
were published in [58]. Chapter 4 presents a mathematical study of ovarian cancer
cellular population growth dynamics and therapeutic administration in vitro. These
results were published in [59]. We then provide a single-cell analysis of cell fate
kinetics in response to prolonged exposure to therapy in Chapter 5. These results
were submitted for publication [60]. Finally, we provide concluding remarks and
discuss future directions in Chapter 6.
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Chapter 2: Mathematical Models of Ovarian Cancers
This review of mathematical models of ovarian cancers was published in [2].
2.1 Overview
In order to systematically investigate the complexity of cancer progression and
response to treatment in ovarian malignancies, integrated mathematical modeling
frameworks viewed from a systems biology perspective are needed. Such integrated
frameworks can offer innovative contributions to the clinical women’s cancers com-
munity, since answers to clinical questions cannot always be reached with contem-
porary clinical and experimental tools.
In the present chapter, we will focus on mathematical models of ovarian cancer
dynamics, and not on statistical modeling (e.g., absolute risk prediction models, or
multiple regression analyses assessing epidemiologic risk factors), or specific algo-
rithmic approaches (e.g., machine-learning approaches to specifying rules for genetic
and molecular stratification of individual patients). Additionally, we will differenti-
ate between mathematical modeling of cancer dynamics or drug resistance and other
related topics such as cancer imaging or detection algorithms, in which mathematics
has historically played an instrumental role [61,62].
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Considerable mathematical modeling effort has been directed so far towards
modeling carcinogenesis, cancer progression, and cancer treatment [61,63–70]. Rel-
atively few mathematical investigations, however, have specifically targeted ovarian
cancers.
After a comprehensive literature search, we note that, to best of our knowledge,
the models presented below represent the majority of the published ovarian cancer
mathematical models. We thus chose to discuss these mathematical models in detail,
and highlight areas where extensions to these in silico modeling frameworks could
be further developed.
2.2 Modeling Disease Natural History and Early Detection Strategies
Focusing exclusively on unimodal TVU screening, Danesh et al. developed
a mathematical model to study the frequency at which ovarian cancer screening
should be done in order to be effective [71]. To model ovarian cancer growth and
progression, Danesh et al. [71] developed a multi-type branching processes model,
where the different types represent stages in the serous epithelial ovarian cancer
progression, without differentiating between the low and high-grade subtypes.
In their model, type 0 cells are present in the primary tumor in the ovary or
Fallopian tube, type 1 cells are floating in the abdominal cavity, and type 2 cells are
attached to the peritoneum. Type 2 cells are assumed to infiltrate the extracellular
matrix and eventually metastasize to distant organs, so that when they are present
in significant (and clinically detectable) numbers, the cancer would be classified as
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stage III.
Therein, cells can transition from type 0 to type 1 and from type 1 to type
2 at differential rates, or give birth to nonmutant offspring or die. The transition
rates between the different cell types were used as rates in a continuous time Markov
chain. In this model, the transitions between cellular types are assumed to involve
migration of cells rather than genetic mutations.
Below, the theorems for the multi-type branching process between cellular
types enable Danesh et al. to quantitatively estimate the behavior of all three cell
types [71].
[Theorem 2.2.1, [71]]








). Here, δ0 is a point mass at 0,
corresponding to the event that the branching process dies out, a0 represents the





→ 1 in probability as t →∞.
[Theorem 2.2.3, [71]]
e−λ2(t−s2)Z2(t) → V2, where V2 is the sum of points in a Poisson process with





)α2Γ(α2), and Γ(r) =∫∞
0
tr−1e−tdt is the Gamma cumulative distribution function (CDF).
In the theorems above, type i cells proliferate with rate ai and die with rate
bi, yielding a net growth rate of λi = ai − bi. Herein, the primary tumor cells grow
with rate λ0, and shed with rate u1 moving into the peritoneal cavity. There, they
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grow with rate λ1, and shed with rate u2 into secondary sites, where they grow with
rate λ2 > λ0.
In order to address their motivating question (i.e., can ovarian cancer be de-
tected early or not?), Danesh et al. introduced the concept of a “window of oppor-
tunity” for screening. It is defined as the difference between the time when cells of
type 2 reach 109 cells (corresponding to a late-stage tumor) and cells of type 0 reach
6.5 · 107 cells (corresponding to the detection threshold).
Using data on tumor growth from Brown and Palmer [72], they concluded
that the window of opportunity corresponds, on average, to 2.9 years, with most
of the distribution concentrated between 2.5-3 years. According to their model,
TVU-based ovarian cancer screening should occur biannually.
The underlying assumption in the Danesh et al. modeling framework is that
metastatic ovarian cancer cells growth at a significantly higher rate than primary
tumor cells. This assumption has yet to be validated clinically.
In contrast to the dynamics portrayed in this work, it is generally believed
that ovarian cancers that present clinically during early stages do not necessarily
represent precursors to cancers that, if left undetected, would otherwise present at
advanced stages [73,74].
Moreover, the theoretical results derived assume exponential stage residence
times and an infinite time period when determining cancer growth and progres-
sion. Using non-exponential growth kinetics and a finite observation time (as done
empirically) could alter the modeling outcomes.
Finally, in contrast to the biannual TVU-based ovarian screening recommen-
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dation based on the Danesh et al. modeling inferences, latest data from ovarian
cancer screening randomized controlled trials demonstrate the failure of annual,
unimodal TVU examinations to improve ovarian cancer detectability and overall
survival rates [19,30].
In another attempt to model the preclinical natural history of serous epithelial
ovarian cancer as a function of tumor size, stage and its implications for TVU-
based screening [72], Brown and Palmer identified and analyzed available reports
on occult ovarian cancers, and used the data in a comprehensive meta-analysis
of published data to model the growth, progression and TVU-based detection of
ovarian cancer [13,35,36].
Data were collected from published studies of healthy germline BRCA1 and
BRCA2 mutation carriers [38, 75], who had their ovaries and Fallopian tubes re-
moved prophylactically. In some of these women, unsuspected ovarian cancers were
discovered upon surgery [76].
Brown and Palmer performed a Monte Carlo simulation of tumor life histories
to fit an exponential in silico model for tumor growth using parameters derived from
their meta-analysis, with separate growth rate parameters for early and advanced
stage cancers. A basic description of the theoretical tumor growth model proposed
by Brown and Palmer is the following:
log size = a+ bt1, (2.1)
log size = c+ bt2. (2.2)
Herein, tumors in both early and advanced stages are assumed to grow expo-
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nentially. Specifically, the early stage tumor growth model is illustrated in Equation
(2.1). Therein, a is the size at which a particular tumor is detectable by histopathol-
ogy, b is the (exponential) growth rate constant and t1 is the time since the tumor
became detectable by histopathology. Detection thresholds for each individually
simulated growth curve were set to match the corresponding value found in the
collected tumor dataset.
The advanced stage tumor growth model is illustrated in Equation (2.2).
Therein, c is the log value of the tumor size at disease progression from early to
advanced stage (estimated from the Monte Carlo simulation of tumor life histories),
d is the difference between the log values of the tumor size at empirical diagnosis
obtained from the collected tumor dataset and the log value of the size at progres-
sion from the generated simulation. Lastly, t2 is the in silico measured time since
progression.
In this model, the “window of opportunity” was defined as the time duration
for early detection, i.e., the time during which the tumor is expected to remain early
stage (localized or regional). They estimated the window of opportunity for TVU
detection of early stage cancers to be around 4.3 years, and predicted that most
detected advanced stage serous cancers would have become advanced a median of
0.8 years prior to detection.
Similar to the Danesh et al. model, the underlying assumption in the Brown
and Palmer quantitative analysis is that ovarian cancers that are clinically present
during early stages are precursors to cancers that if left undetected, would otherwise
present at an advanced stage. We point out that a timely detection of low volume
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ovarian cancer, which does not necessarily represent early stage disease, should be
the goal of any screening studies as well as of any mathematical modeling framework
aimed at exploring screening scheduling.
To assess dynamic plasma biomarker kinetics in relation to the genesis of
cancer, Hori and Gambhir incorporated tumor growth into a linear one-compartment
biomarker secretion model, beginning with a single parental tumor cell1 [77]. They
aimed to quantify the time required for a growing malignant tumor cell population
to reach a sufficient size so that its shed blood biomarker levels were high enough
to be detectable by current clinical blood biomarker assays.
The model was used to calculate changes in the detection capability based on
log-order perturbations in the parameters related to biomarker shedding. Tumor
cell growth was represented by either the exponential or Gompertzian model, while
the healthy cell population was assumed constant.




= uT (t) + uH(t)− kELqEL(t), (2.3)
uT (t) = fPL,TRTNT (t), (2.4)
uH(t) = fPL,HRHNH(t), (2.5)








NT (t) = NT,0e
kGRt, (2.7)
The change in the mass of the plasma biomarker with respect to time is equal to the
difference between the influx of plasma biomarker shed by the tumor cells, uT (t),
healthy cells, uH(t) and the outflux of biomarker from the plasma, qEL(t). This
phenomenon is illustrated in Equation (2.3).
The rate of biomarker entry into the plasma is the sum of the input from tumor
cells (as modeled in Equation (2.4)) and from healthy cells (as modeled in Equation
(2.5)). Tumor cell growth is represented here by either the Gompertzian growth
model (see Equation (2.6)), or the exponential growth model (see Equation (2.7)).
The healthy cell population is assumed to remain constant throughout simulation
time, and is set at NH(t) = NH,0.
Hori and Gambhir aimed to identify the biomarker-related parameters that
would most greatly impact blood-based early cancer detection. Specifically, their
goal was to quantify how far each baseline parameter value would need to change in
order to achieve earlier, sub-millimeter tumor detection. It was found that tumors in
the mm diameter range could only be detected under ideal conditions of extremely
high rates of biomarker secretion by tumor-associated cells and zero background
level from healthy cells.
Hori and Gambhir thus concluded that clinical implementation of a CA125
biomarker-based early serous epithelial ovarian cancer detection would be extremely
difficult for the time being. We note that the relationship between tumor sizes and
16
CA125 biomarker levels is not entirely understood [30] and serial CA125 measure-
ments are not common practice [19, 23, 78]. Further modeling efforts could poten-
tially drive further cohort screening studies.
2.3 Modeling Therapeutic Targeting and Treatment
A key question related to optimal sequencing and scheduling of chemotherapy
and surgery is whether the optimal therapeutic strategy would be to maximally
debulk a cancerous tumor followed by chemotherapy or vice versa [79–81].
Kohandel et al. [82] considered one population of tumor cells, a non-cell cycle
phase specific drug, and various growth/cell-kill laws in order to compare two ap-
proaches for therapy: a) chemotherapy followed by surgery, or b) surgery followed
by chemotherapy.
The authors combined Gompertzian and generalized logistic growth models
with different cell-kill hypotheses, and assumed that surgery instantaneously kills a
fraction of the tumor cells at the time of the treatment. For both the Gompertzian
and generalized growth models, chemotherapy followed by surgery proved to be the
optimal approach.
The one-compartment ODE model of Kohandel et al. is illustrated below.
dN
dt




c(t)N, if log − kill model,
c(t)f(N), if NS model,
c(t) N
N+δ
, if Emax model
(2.9)
Equations (2.8)-(2.9) govern the dynamics of the tumor growth, under the surgical
and chemotherapeutic treatments. Specifically, the dynamics of the number of tumor
cells at time t, N(t), is described by differential functional forms for the growth law,
where f(N) is the tumor cell growth dynamics (e.g., f(N) = aN for the exponential
growth law, where a is the constant proliferation rate). Moreover, G(t, N) describes
the effects of the drug on the system , and I(t = tsurgery) is an indicator function
(equal to 1, if t = tsurgery, and 0 otherwise). Possible differential functional forms for
G(t, N) are provided in Equation (2.9). Surgery is assumed to be instantaneous, and
to remove a fixed fraction of eks of tumor cells, where ks is the fraction of removed
cells during surgery.
The results presented are general and independent of a particular choice of
parameters or drug administration protocols. However, in contrast to the math-
ematical modeling results, recently performed meta-analyses of randomized trials
comparing chemotherapy versus surgery for initial treatment in advanced ovarian
epithelial cancer [83] as well as locally advanced breast cancer [84] showed no dif-
ference between the two clinical scenarios in terms of survival or overall disease
progression.
We note that a key assumption of the Kohandel et al. model is that chemother-
apy administered prior to surgery solely alters primary tumor growth, rather than
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also affecting the formation and growth of (micro)metastatic tumor foci, which could
be clinically occult at the time of surgery.
The clinical rationale for adjuvant chemotherapy (i.e., after surgical resection)
is to eliminate any systemic, distant microscopic disease that would most likely al-
ready be present pre- or post-surgical resection. A future mathematical investigation
based on the Kohandel et al. model could, for example, address the open clinical
question of how to reliably identify the subsets of patients without any microscopic,
residual disease, who would not benefit from adjuvant chemotherapy.
In a different attempt to model combination therapy, Jain et al. developed
a mathematical model of ovarian cancer xenograft growth to study the effect of
carboplatin and ABT-737, a small-molecule inhibitor of anti-apoptotic proteins Bcl-
2 and Bcl-xL, on tumor growth inhibition [85].
Their model of ovarian cancer growth and treatment was based on a coupled
system of ODEs and PDEs [86,87], representing the temporal dynamics of prolifer-
ating and arrested cancer cells, and using the concentrations of the two drugs inside
the peritoneum, plasma and tissue.
This combination therapy model carefully accounted for the pharmacodynam-
ics and pharmacokinetics of both drugs, and was calibrated against in vivo ex-
perimental data collected from xenografted mice treated with carboplatin and/or
ABT-737 on a fixed period schedule [85]. Their goal was to study dosage/timing
combinations of the two drugs leading to the fastest time to minimal residual dis-
ease, or to the minimization of total drug in order to achieve a predetermined tumor
growth inhibition.
19
Simulations of the Jain et al. model suggested that when combined with ABT-
737, the infusion time of carboplatin doses together with the AUC of the drug were
the most important predictors of the tumor long-term response to the combination
therapy.
While the model is validated by in vitro ovarian cancer cell lines xenografted
from patient ascitic tumor cells, further clinical investigations are needed to explore
and examine the synergy between carboplatin and Bcl-2 family inhibitors.
Lastly, a two-compartment linear ODE model proposed by Panetta attempted
to mathematically derive optimal treatment strategies in the sense of promoting the
largest ovarian tumor cell burden reduction [88]. The two-compartment cell cycle
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, if nT ≤ t ≤ a,
0, if a+ nT < t ≤ (n+ 1)T.
(2.11)
In the system of equations illustrated in Equation (2.10), P is the number of pro-
liferating tumors cells, and Q is the number of quiescent tumor cells. Additional
parameters include γ, the growth rate of proliferating cells, α, the transition rate
from the proliferating to the quiescent compartment, δ, the natural proliferating cell
death rate, β, the transition rate from the quiescent to the proliferating compart-
ment, and λ, the natural quiescent cell death rate.
All parameters in the model are assumed to be positive, and constant. Herein,
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the system outlined in Equation (2.10) represents a linear system of ODEs modeling
the dynamics of the proliferating and quiescent cell compartments. The function
f(t) described in Equation (2.11) represents a step function describing the effects of
the chemotherapeutic treatment, e.g., paclitaxel.
The periodic function modeling the paclitaxel effects is assumed to target only
the proliferating cell compartment. In its functional representation, s is the strength
of the drug, a is the active drug time, T is the period of paclitaxel administration
and n stands for the nth administered drug dose.
Using clinical variables such as treatment period, drug-infusion time, and pro-
liferative fraction of ovarian cancerous cells, Panetta quantitatively demonstrated
that for short periods (i.e., close to the active phase time) more drug is required in
order to achieve a decay in the ovarian cancer cell population.
2.4 Modeling In Vitro Invasive Cancer Cell Kinetics
To simulate in vitro cancer-cell kinetics after cisplatin administration, Mon-
talenti et al. developed a linear model of cell-cycle phase transitions based on
experiments using IGROV-1 ovarian cancer cell line [89]. They used flow cytometry
variables (derived experimentally) as the input to a quantitative description of the
action of cisplatin on the carcinoma cells.
The aim was to specifically model the time between cell-cycle phases, delays
and block-effects, with consequent repair or cell mortality following the exit from the
blocks. It was assumed that drug administration forces cells to leave asynchronous
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growth, with the main effects being cell death, cell-cycle phase delays, or cell-cycle
blocks. At the end of each cell-cycle phase, cells were assumed to progress to the
next phase only if they passed an internal molecular checkpoint.
Montalenti et al. [89] considered various levels of complexity in their cell-cycle
simulation: a) inter-cell differences in phase duration (modeled via a two-parameter
probability distribution of the likelihood of a cell of a certain phase age leaving the
specific phase); b) the probability that a cell can either bypass the quiescent phase
or enter it for an indefinite period of time; and c) the probability that cells can be
killed by cisplatin at a distinct rate in every phase, blocked but then repair damage
and recycle, or frozen in a specific age compartment, inhibiting age maturation.
While a certain amount of information could be obtained by visual inspection
of the raw experimental data performed and used, the task of the parameter-fitting
simulation was to consider all experimental data together with a number of drug
doses and recovery times, in order to derive a coherent kinetic scenario. Once the
input baseline set of kinetic parameters was determined, the data were simulated
on the cisplatin-treated IGROV-1 cells using a trial-and-error-procedure to find
biologically appropriate estimates of the cisplatin-induced delays, block effects and
cell mortality induced at every cell-cycle phase.
The Montalenti et al. modeling results yielded a very detailed kinetic descrip-
tion of the IGROV-1 cell cycle dynamics treated with cisplatin [89]. It remains
unclear whether their modeling inferences can be easily translatable to human ovar-
ian cancer tumor-drug interactions, an issue that warrants further exploration.
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2.5 Modeling Stem Cell Dynamics
To estimate stem cell self-renewal probabilities in serous epithelial ovarian
carcinomas, Ciampi et al. proposed a method for estimating the probability of self-
renewal of serous epithelial ovarian tumor stem cells starting from experimentally
derived distributions of clonal colonies obtained in cell culture [90].
The model was based on tumor cell populations being composed of a) tumor
stem cells, capable of self-renewal and subsequent tumor self-regeneration; b) tran-
sitional cells, not capable of self-renewal but characterized by a limited potential
for further proliferation (i.e., de-differentiation); and c) end-stage cells, incapable of
further proliferation, and thus considered terminally differentiated.
The proliferation of the cancer cell population was treated as a multi-type
Galton-Watson process in which stochastic fluctuations lead to probability distribu-
tions in the number of each cell type, under the assumption that cell division does
not necessarily occur at the same time for same-age cells.
Using a Nelder-Mead algorithm and equating the theoretical moments of the
distribution of cell types with the observed experimental colony size mean and vari-
ance, Ciampi et al. derived parameter estimates for the probability of self-renewal
of a tumor stem cell, and the clonal expansion number expressed in the generations,
i.e., the number of de-differentiated states.
We note that a key assumption of this model is that ovarian cell populations are
organized in a hierarchy of decreasing proliferation potential and increasing degrees
of cellular differentiation. However, it is unclear if stem cells are responsible for the
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initiation and progression of clinical ovarian cancers [91].
Moreover, the lack of unique markers that are able to identify stem cells in the
context of ovarian cancers make it difficult to characterize the proliferative landscape
of such cells in vitro or in vivo.
2.6 Remarks
From a mathematical point of view, the quantitative tools employed in the
models described in Sections 2.2 - 2.5 range from probabilistic techniques (e.g.,
branching processes, bootstrap resampling, time-homogeneous Markov chains), through
differential equation-based approaches (e.g., single or multiple compartment ODEs,
PDEs or coupled ODE-PDE models).
There are, however, several underlying limiting assumptions with using such
modeling approaches. Most such models rely on the “perfect mixing” assumption
that cellular populations are spatially homogeneous, and are only able to quantify
average cellular behavior, rather than heterogeneous genetic and phenotypic cellular
profiles.
In doing so, existing models are only able to generate aggregate statistics
or outcomes similar to results derived from population-based cohort studies. The
extent to which such modeling results would contribute to understanding patient-
specific cancer progression or subsequent therapeutic outcomes is thus unclear, but
remains an active area of exploration.
Studying the natural history, growth, progression or dynamic response to treat-
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ment of breast and ovarian cancers in an integrated systems biology/mathematical
framework represents a complementary tool at the disposal of the women’s cancers
clinical community. If accurately and realistically applied to existing clinical data,
such frameworks could represent a substantial step forward, and can be performed
in a relatively inexpensive manner, that relies only on computing power.
Mathematical modeling could thus provide insights about the disease dynamics
that reach beyond contemporary clinical and experimental tools and are impossible
to obtain even in large-scale cohort studies. Dynamic spatiotemporal mathematical
models of women’s cancers and their evolution could provide a quantitative under-
standing of the likelihood of occurrence of specific clinical scenarios in response to
detection, treatment and the when and the why of emergence of resistance.
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Chapter 3: Modeling the Dynamics of High-Grade Serous Ovarian
Cancer Progression for Transvaginal Ultrasound-Based
Screening and Early Detection
The results in this chapter were published in [58]. It focuses on a mathematical
study of ovarian cancer initiation, progression, and detection in silico.
3.1 Introduction to HGSOC Detection Methods
The five-year survival rate for all ovarian cancer stages in the US has improved
from ∼ 30% in 1970 to ∼ 46% in 2017. This is a result of risk-reduction prophylactic
surgeries for high-genetic risk cases, the improved administration of taxane and
platinum chemotherapies, and the extended life expectancy of the affected patients
[92].
Despite this recent progress, ovarian cancer still remains the most fatal gy-
necologic cancer [4]. By the end of 2017, it is estimated that 22,440 new cases of
ovarian cancer and 14,080 deaths related to this disease will occur [4].
The inability to detect aggressive, early stage ovarian cancer has substantial
implications for the reported low post-diagnosis survival rates. This is possibly, in
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part, due to the natural history of ovarian cancers, since most women with local-
ized disease present vague symptoms such as pelvic or abdominal pain, abdominal
bloating, urinary urgency or frequency, and early satiety [7].
A recently proposed morphomolecular characterization of ovarian cancers un-
derscores the importance of clear separation between the various subtypes of ovarian
cancers with respect to the appropriate future therapeutic targeting [93]; therein, it
is reported that epithelial ovarian cancers account for 85 - 90% of ovarian cancers,
with a subset of epithelial ovarian cancers, HGSOCs representing nearly 70% of all
ovarian cancer cases.
Existing early detection screening strategies for other cancer types, including
prostate, colon, breast and cervical cancers, raise the question of whether HGSOC
is amenable to similar screening strategies. Emerging insights into HGSOC’s dis-
ease progression suggest that early detection of low volume advanced stage, rather
than large volume early stage HGSOC, may be a more clinically actionable goal
of screening studies. This is because five-year relative survival rates for advanced
stage cancers at diagnosis are significantly lower than for early stage cancers at
diagnosis [7, 23, 73,76,94].
3.1.1 Ultrasound and CA125 Blood Levels Testing
Transvaginal-ultrasound (TVU) represents an integral part of all reported ma-
jor ovarian cancer screening trials, despite its well-recognized limitations (e.g., bi-
lateral disease, or multiple foci spread throughout the peritoneal cavity). TVU is
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accurate in detecting abnormalities in ovarian volume and morphology, but is less
reliable in differentiating benign from malignant tumors. Serum biomarkers (CA125,
HE4) testing, pelvic examinations, or simultaneous TVU and CA125 testing have
also been examined as non-invasive tools for detecting early stage ovarian cancer in
general-risk women.
However, mounting evidence suggests that annual screening with TVU and
serum biomarkers does not reduce mortality [5,30]. Furthermore, high false positive
rates leading to intervention are associated with potential harm, such as unnecessary
surgical intervention and related complications.
The lack of utility of such screening tools is possibly due to the absence of
adequate TVU sensitivity in detecting small increases in tumor volume and dis-
tinguishing between malignant and benign cases. The addition of serum biomark-
ers testing (e.g., CA125 levels) does not improve early-stage detection levels, ei-
ther [19, 40,95,96].
The largest ever ovarian cancer screening study of 202,638 general-risk women
demonstrated that multimodal screening including serial TVU and CA125 level
testing yielded a 15% mortality reduction rate compared with a 0% no screening
or 11% unimodal TVU-based screening cohort mortality reduction rate over 0-14
follow-up years [19].
However, this study also showed increased CA125 levels can be detected in
benign conditions, rendering it inadequate for use in screening asymptomatic women
for early-stage ovarian cancer. The lack of adequate early-detection tools might
be explained by the fact that any epithelial ovarian cancers diagnosed in stage I
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might be fundamentally different from those diagnosed in advanced stages, which
are preponderantly high and not low-grade cases [94].
As a result, whether HGSOC constitutes a valid target for ovarian cancer
screening remains unanswered and highly contentious with respect to either general-
risk or high genetic-risk women, such as germline BRCA1 and BRCA2 mutation
carriers, or women with a significant family history of breast or ovarian cancer. A
quantitative invalidation of TVU as an effective HGSOC screening strategy is a
necessary next step.
3.1.2 Model Findings
Herein, we propose a mathematical model for a quantitative explanation on
the reported failure of TVU-based screening to improve HGSOC low-volume de-
tectability and overall survival.
We develop a novel in silico mathematical assessment of the efficacy of a
unimodal TVU monitoring regimen as a strategy aimed at detecting low-volume
HGSOC in cancer-positive cases, defined as cases for which the inception of the
first malignant cell has already occurred. Our findings show that the median win-
dow of opportunity interval length for TVU monitoring and HGSOC detection is
approximately 1.76 years. This does not translate into reduced mortality levels or
improved detection accuracy in an in silico cohort across multiple TVU monitoring
frequencies or detection sensitivities.
We demonstrate that even a semiannual, unimodal TVU monitoring protocol
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is expected to miss detectable HGSOC. Lastly, we find that ∼ 50% of the simulated
HGSOC growth curves never reach the baseline detectability threshold, and that
on average, 5 - 7 infrequent, rate-limiting stochastic changes in the growth param-
eters are associated with reaching HGSOC detectability and mortality thresholds
respectively.
Our mathematical model captures the dynamic, temporal evolution of HGSOC
progression. It is consistent with recent case reports and prospective TVU screening
population studies, and provides support to the empirical recommendation against
frequent HGSOC screening.
3.2 Modeling Approach and Assumptions
We develop an in silico mathematical framework modeling incipient HGSOC
growth kinetics in an untreated scenario, subject to stochastic heterogeneous fluctu-
ations. Herein, we refer to an untreated HGSOC as a radiographically detected, clin-
ically asymptomatic, treatment-free malignancy in which no surgery and/or other
systemic therapies has yet been performed/administered.
Inspired by a stochastic numerical model of breast cancer growth [97], we
follow a similar approach to model HGSOC natural history and progression until
clinical TVU detectability. The key feature of this model incorporated in the present
work involves modeling HGSOC progression as Gompertzian growth kinetics further
characterized by infrequent, rate-limiting stochastic changes in the growth parame-
ters.
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3.2.1 HGSOC Growth Estimation
To estimate a lower bound for the initial HGSOC growth rates, we identified
the existing TVU-based screening study with the largest cohort of ovarian cancer
patients [98]. In this study, data concerning ovarian volumes were obtained from
13,963 patients who were undergoing annual TVU examinations from 1 to 11 years.
We define abnormal ovarian enlargement as two standard deviations above
normal ovarian volume in pre- and postmenopausal women, see [29, 98, 99]. Based
on 58,673 ovarian volume observations, the upper limit for normal ovarian volume
therein was found to be 20 cm3 for pre- and 10 cm3 for postmenopausal women [98].
Menopause is defined as occurring 12 months after a womans last menstrual cycle
and confirmed by follicle stimulating hormone levels > 40 IU/L [100].
We subsequently assume that any HGSOC tumor volume larger than the dif-
ference between the two pre-defined thresholds would represent a suspicious TVU
finding, and subsequently be diagnosed as a radiographically detectable HGSOC
case.
The data points illustrated in Figure 3.1 represent estimated lower bounds
for the initial HGSOC rates used to initialize our model. They correspond to 9
reported HGSOC clinical findings based on TVU examinations of adnexal ovarian
regions available 12 months or fewer prior to the preoperative diagnosis time of the
malignancy [101]. The reported cases showed no apparent ovarian volume abnor-
malities 2 to 12 months prior to TVU diagnosis.
We note that, to the best of our knowledge, these findings represent the only
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available temporal data on the progression of previously occult, radiographically
detected HGSOCs.
HGSOC-growth curve time is measured from the inception of the first malig-
nant cell until the time needed to reach the baseline TVU detection threshold, or
until the baseline life-threatening tumor volume is reached. Herein, we assume that
the minimum, baseline TVU detectability threshold for a cancer-positive case is 10
cm3 (equivalent to 1010 cells, or to a 2.673 cm spherical HGSOC tumor diameter).
Similarly, we follow the definition of the life-threatening untreated HGSOC
tumor volume to be 103 cm3 (equivalent to 1012 cells, or to a 12.407 cm spherical
tumor diameter), as previously published [102]. The two thresholds can be adjusted
if more sensitive diagnostic techniques are developed, or if different life-threatening
untreated HGSOC tumor volume values are used.
We assume the cell number-to-volume conversion to be 1 cm3 = 109 HGSOC
cells. The baseline thresholds were chosen to estimate conservative lower bounds for
the time of TVU diagnosis and time of reaching the life-threatening tumor volume
distributions. Herein, we define the window of opportunity interval as the difference
between the two thresholds based on the growth curves that reach both endpoints.
3.2.2 Modeling Equations
We use the incipient HGSOC growth kinetics model to study the timing of
HGSOC initiation relative to reaching TVU detectability and the life-threatening
untreated tumor volume sizes, as defined above, and its subsequent implications on
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Figure 3.1: Reported bi-dimensional measurements of 9 incidental, previously un-
detected HGSOC tumor sizes (length, width) were converted into a weighted, one
dimensional measurement (i.e., spherical radius): weighted radius r =
√
a · b, where
a and b are the radii of the minor and major axes of an ellipsoid, respectively. To
compute initial tumor volumes, we assume tumors to be spherical and compute their
volume according to the formula 4π3 r
3cm3. We assume normal ovarian volumes were
20 cm3 for the pre- and 10 cm3 for the postmenopausal women reported in Table 1
of [98]. We estimate the lower bounds for the initial HGSOC growth rates as fol-
lows: initial growth rate = ln(tumor volume at diagnosis) − ln(normal ovarian volume)T , where
T represents the number of days between the timing of the previous, non-suspicious
TVU examination and the malignancy diagnosis. Each point plotted (case number,




Occult growth curve in silico HGSOC growth curve that never
reaches TVU detectability.
Succumbed growth curve in silico HGSOC growth curve that reaches
both a TVU-detectable and life-threatening
tumor volume in between consecutive
TVU monitoring events.
Cancer-positive growth curve in silico HGSOC growth curve in which the inception of
the first malignant cell has already occured.
Untreated growth curve in silico HGSOC growth curve described as
radiographically detected, treatment-free
malignancy in which no surgery/therapy has yet
been performed/administered.
Table 3.1: Definitions used throughout the model
TVU monitoring protocols.
We choose to use the terminology “TVU monitoring” in lieu of “TVU screen-
ing”, as the latter would be a more appropriate term for a detection strategy focused
on a cohort of cancer-negative, general- or high-risk otherwise asymptomatic healthy
women [99], as opposed to a pre-selected, biased in silico cancer-positive cohort, for
which the former term is more appropriate.
A main study end point for this model was HGSOC-specific mortality, specif-
ically the number of in silico HGSOC growth curves that would be missed even
under frequent TVU monitoring.
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To this end, we developed a mathematical framework modeling incipient un-
treated HGSOC volume growth in order to satisfy two purposes: one, to simulate
the natural history of the malignancy, and two, to quantify the relationship between
TVU monitoring frequency and detection time of a non-life-threatening HGSOC
volume.
To obtain a temporal estimate of the effective growth behavior of a simulated
HGSOC growth curve, we let N(t) be the total HGSOC tumor volume, i.e., the
number of HGSOC cells located in the primary tumor site (e.g., one of the ovaries,
or the Fallopian tubes) at time t. N0 represents the initial, pre-diagnosis HGSOC
cell count, set as 1 for computational convenience. Time t is measured since the
inception of the first malignant cell.
If we let kgrowth represent the initial HGSOC growth rate constant and kdecay
describe the growth saturation rate, where both parameters have the dimension
of inverse time (e.g., in our case, day−1), the Gompertz function modeling tumor






N(0) = 1. (3.2)
The normalized N(t) thus satisfies the following differential equation:
dN
dt
= N(t)[kgrowth − kdecay lnN(t)]. (3.3)
The carrying capacity N(∞) is assumed to be finite and nonzero. It follows
that kdecay > 0, and that N(∞) = e
kgrowth
kdecay > 1. To find the inflection point of N(t),
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that is Ni(ti), we require
d2N
dt2




i.e., the derivative of the change in HGSOC growth rate is set as 0.















, N∞ = eNi. In this case, the tumor cell burden
can outgrow its size at the inflection point by a factor of e. The inflection point
represents a turning point in the dynamics when the observed growth trend starts
decelerating.
Nonetheless, while the Gompertz equation describes a density-dependent growth
rate, it does not account for any stochastic irregularities, e.g., stepwise growth pat-
terns, also see [97]; such temporary Gompertzian plateaus (i.e., cessation in tumor
growth) may be correlated, as reported in vitro, with tumor dormancy in ovarian
cancer spheroids [103,104], human ovarian cancer cell lines [105,106], or in vivo with
tumor xenografts implanted in mice [105], and may be associated with dormancy in
untreated, undetectable HGSOC.
Thus, a constant growth rate might not be feasible to model progression. To
this end, by incorporating rare but relatively large jumps in the growth saturation
rate kdecay, we assume that HGSOC growth slows down due to adverse environmental
conditions (e.g., reactive O2 presence, nutrient depletion).
The irregular tumor growth kinetics illustrated in our model accounts for the
observed heterogeneity in the progression of clinical HGSOCs [107] and highlights
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Figure 3.2: The initial HGSOC growth rate and decay values, kgrowth and kdecay,
respectively and their ranges are as reported in Table 3.2.
the differential HGSOC natural histories that lead to identical clinical outcomes or
presentations (e.g., see case numbers (4) and (11) reported in Table 1 of [101]). The
tumor growth kinetics represented herein could thus be phenomenologically valid
both in vivo and in vitro.
3.2.3 Modeling Assumptions
The definitions used throughout the implementation of the HGSOC carcino-
genesis, growth and progression model are provided in Tables 3.1. A flowchart of
the computational model is shown in Figure 3.2.
We assume the inception of the first HGSOC malignant cell occurs sometimes
during premenopausal years, and thus we increment time in intervals of 28 days
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Parameter Value Unit Simulated Range
kgrowth Median = 0.0133 day





N0 1 cell -
α Median = 0.015 - 0.0094 − 0.015
Table 3.2: Herein, kgrowth represents the initial HGSOC growth rate, kdecay denotes
the initial HGSOC growth saturation rate, and N0 represents the initial, pre-diagnosis
HGSOC cell count. The convention for the cell number-to-volume conversion used is
1 cm3 = 109 cells. Moreover, α denotes the probability of random change in kdecay.
Its value is subsequently updated according to the algorithm illustrated in Figure 3.2.
(the average length of a menstrual cycle [108]) for a total number of 460 menstrual




. Varying this initial parameter would not yield substantially different
median or range values for the estimated cdf’s.
We then implement the changes in the initial growth saturation rate, kdecay,
in a two-step manner. First, we generate a number α ∼ lnN(10−2, 25 · 10−2), that
is log-normally distributed with mean = 10−2, variance = 25 · 10−2, and range
= 0.0094 - 0.150 (0.01 mean probability of change in each 28-day period, or 26%
mean probability of change in 2 years). Herein, α refers to the probability of random
change in kdecay.
In order to implement conservative estimates for the clinically occult random
variable α, we choose an asymmetric, right-skewed probability distribution function.
Second, we check whether α is less than a randomly generated number between 0
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Volume (cm3) Cell-number count (cells) Equivalent spherical
tumor diameter
0.5 0.5 ·109 0.98
1 109 1.24
1.5 1.5 · 109 1.42
10 1010 2.67
20 2 · 1010 3.36
1000 1012 12.4
Table 3.3: Cell-number-to-volume and tumor diameter conversions used throughout
the model.
and 1. If that is the case, we then generate a second random number between 0
and 1 and compute the updated kdecay as kdecay =
previous kdecay
1+random number
. We then allow
the number of HGSOC cells, N(t), to follow the Gompertzian growth law until
the probability of a random change in kdecay occurs again, which leads to another
update.
Given a fixed carrying capacity, varying either kgrowth or kdecay makes little
qualitative difference from a mathematical perspective; we can thus infer that mod-
ifying either parameter yields similar qualitative effects.
From a molecular perspective, we chose to focus on changes in the initial HG-
SOC growth saturation rate, kdecay, as these infrequent, rate-limiting changes could
be associated in part with the several (epi)genetic alterations in tumor suppressor
genes and/or changes in genes involved in DNA damage repair pathways.
Reducing the growth saturation rate, kdecay, of the HGSOC tumor cell burden
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the program increases the current HGSOC carrying capacity, N(t) in a stochastic
fashion. Changes are globally implemented, meaning that once a stochastic jump
in kdecay occurs, cells proliferate according to the newly updated Gompertz-type
growth law.
3.3 Numerical Results
3.3.1 Model Simulation Of HGSOC In Silico Growth Curves
Five representative growth curves generated by the HGSOC model in our sim-
ulated cancer-positive cohort are illustrated in Figure 3.3.1. The baseline parameter
set and cell-number-to-volume and tumor diameters conversions as reported in Ta-
bles 3.2 and 3.2.3 are used.
By incorporating rare but relatively large jumps in the growth saturation rate
kdecay, we illustrate how a HGSOC volume grows in stepwise patterns and may
not increase for relatively large amount of time (see Figure 3.3.1), as opposed to
exhibiting a constant doubling time. This approach also enables us to generate a
distribution of heterogeneous pre-clinical HGSOC natural histories in an in silico
cancer-positive cohort.
Statistics generated from one representative simulation of the HGSOC growth
and progression model using n = 1000 HGSOC growth curves are reported in Table
3.3.1. Therein, the generated data illustrate the time needed to reach the baseline
TVU-detectable HGSOC volume of 10 cm3, the baseline life-threatening tumor vol-
ume of 103 cm3, and the window of opportunity interval length. The number of
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Figure 3.3: This sample simulation of the HGSOC progression model illustrating
five representative growth and progression curves is generated using the same base-
line parameter set outlined in Tables 3.2 and 3.2.3. Each of the representative growth
curves is an independent realization of the HGSOC stochastic growth and progression
model, initialized with the same parameter value set. Values the baseline TVU de-
tectability and life-threatening untreated tumor threshold are as reported previously.
In this representative simulation, two curves reach the detection threshold (lower solid
line) in 16.4 and 31.2 years, respectively, and life-threatening tumor volume thresh-
old (upper solid line) in 19.3 and 32.6 years, respectively. The calculated window of
opportunity interval length is thus 2.9 and 1.4 years, respectively. One curve reaches
only the detection threshold, in 35.0 years, and two curves remain below both thresh-
olds. Time is measured since the inception of the first HGSOC cell. The curves are
sorted from left to right. Note that the probability that a random change in kdecay
occurs is independent of whether current carrying capacity is reached or not.
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HGSOC growth curves that never reach the TVU baseline detectability threshold
(occult), or the life-threatening threshold (succumbed) are also reported therein.
Subsequent results reported below are based on the same computation that yielded
the data generated in Table 3.3.1.
Baseline parameters used to simulate n = 1000 HGSOC growth curves are
as specified in Table 3.2. Here, the following definitions are used: TD = min
[t ≥ 0 such that N(t) = 1010 cells], TLV = min [t ≥ 0 such that N(t) = 1012 cells],
WOP = TLV - TD, occult represents the number of HGSOC growth curves that
never reach the detectability threshold (i.e., TD = 0), and regressed represents
the number of HGSOC growth curves that never reach the life-threatening size
threshold (i.e., TLV = 0). Cell-number-to-volume and tumor diameter conversions
are reported in Table 3.2.3.
The number of HGSOC growth curves that never become detectable (n =
509), and life-threatening, respectively (n = 582) are subtracted from n = 1000
simulated HGSOC growth curves in the monitoring frequency analysis. Notice that
it takes approximately 26 years for a representative HGSOC growth curve to become
detectable, and about 27 years for an untreated HGSOC growth curve to become
life-threatening. The expected window of opportunity interval length for curves that
reach both thresholds is expected to be concentrated around 1.8 years.
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Statistic TD (years) TLV (years) WOP (years)
Median 25.85 27.3 1.76
Mean 25.7 26.73 2.6
STD 7.94 7.4 2.85
Min. 4.14 4.75 0.3
Max. 38.43 38.6 2.35
Table 3.4: Statistics generated from one sample simulation of the HGSOC growth
and progression model illustrating the time needed to reach the baseline TVU de-
tection threshold (TD), the baseline life-threatening tumor volume (TLV), the du-
ration of the window of opportunity interval (WOP = TLV - TD), and the number
of HGSOC growth curves that never reach TVU baseline detectability (occult), or
the life-threatening threshold (regressed) volumes, respectively, during the sample
simulation.
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3.3.2 Number of HGSOC Carcinogenetic Events Leading to HGSOC
Growth and Progression
Computational results indicate that for the 491 sample HGSOC growth curves
that reach the baseline TVU detection threshold, the number of infrequent, rate-
limiting events associated with changes in the initial growth saturation rate, kdecay
is around 7 (median = 7, mode = 6, range = 3 10, see Figure 3.4). Interestingly,
for this representative simulation, the mode number of required events was 5, and
the reported maximum of such events was 10.
Note also the substantial heterogeneity in the number of events required to
lead to a TVU-detectable HGSOC tumor volume. Similarly, for the 418 growth
curves that reach the baseline life-threatening tumor volume threshold, the number
of rate-limiting events associated with changes in the initial growth saturation rate,
kdecay, is around 7 (median = mode = 7, range = 4 - 10, see Figure 3.4), and the
reported maximum of such events was 10.
Note again the substantial heterogeneity in the number of events required to
lead to a life-threatening, untreated HGSOC tumor volume since the inception of the
first malignant cell. One or two extra events are required in order for a detectable
HGSOC tumor volume to become life-threatening.
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Figure 3.4: In one representative simulation of the model generating 1000 cancer-
positive initially clinically occult HGSOC growth curves, (A) 491 sample HGSOC
growth curves progress to reach the detectability threshold and (B) 418 reach the life-
threatening volume threshold. (A) We record the frequency of rate-limiting events
associated with changes in the initial growth saturation rate, kdecay out of the n =
491 growth curves. For this representative simulation, the mode and median number
of such events are 5, and 7 respectively. (B) We record the number of rate-limiting
events associated with changes in the initial growth saturation rate, kdecay, out of n
= 418 growth curves. For this representative simulation, the mode and median of the
number of such events are 7, and 7 respectively. A maximum number of 10 events
associated with changes in the initial growth saturation rate, kdecay, is recorded in
both panels.
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3.3.3 Estimating the Window of Opportunity Interval Length
To produce estimates of the duration of HGSOC’s pre- and post-diagnosis
phases, we report the generated value ranges (median, range), with median values of
the times needed to reach baseline TVU detection threshold, baseline life-threatening
tumor volume, and the window of opportunity interval length; we chose to report
median values as the median was a more robust statistic compared to the mean
throughout all sample model simulations, and thus constitutes a more accurate
descriptor of the aggregate cancer-positive HGSOC population dynamics.
The model-generated empirical cumulative distribution functions (cdf’s) for
reaching the baseline detection threshold, the baseline life-threatening tumor vol-
ume, and the window of opportunity length interval are reported in Figure 3.5. For
this representative simulation, a total of 498 growth curves reach the baseline TVU
detection threshold (median = 26.7 years, range = 4.52 38.5), a total of 418 growth
curves reach the baseline life-threatening tumor volume threshold (median = 27.65
years, range = 7.28 38.6), and a total of 418 growth curves reach both thresholds,
and are thus included in the window of opportunity interval length computation and
cdf estimation (median = 1.76 years, range = 0.3 14, see Figure 3.5, panel C). As
an alternative to panel C, we illustrate in panel D the fraction of radiographically
detected, treatment-free HGSOC growth curves that progress to the life-threatening
volume threshold is illustrated. Increasing the number of simulated HGSOC growth
curves (n > 1000) does not yield substantially different median or range values for
the estimated cdf’s.
46
Figure 3.5: Empirical cumulative distribution functions for (A) time until base-
line TVU detection threshold is reached (TD); (B) time until life-threatening tumor
volume is reached (TLV); (C) the window of opportunity interval length; (D) the
fraction of radiographically detected, treatment-free HGSOC cases that progressively
reach the life-threatening threshold starting from the baseline detection threshold
time. The progression of n = 1000 HGSOC growth curves is simulated in order to
determine typical empirical cumulative distribution functions for (A) time until base-
line TVU detection threshold is reached (median = 26.7 years, range = 4.52 - 38.5);
in this sample simulation, a total of 498 growth curves reach this threshold; (B) time
until life-threatening tumor volume is reached (median = 27.65 years, range = 7.28
- 38.6). In this sample simulation, a total of 418 growth curves reach this threshold;
(C) window of opportunity interval length (median = 1.76 years, range = 0.3 - 14).
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3.3.4 Assessing the Feasibility of Multiple Frequency TVU Monitor-
ing Protocols
Figure 3.6 illustrates the relative proportions of HGSOC curves that remain
occult (first, black horizontal column), that are detectable in the first or subse-
quent TVU monitoring events (second, grey horizontal column), and lastly, that
are succumbed (third, white horizontal column) out of n = 1000 simulated HGSOC
growth curves. Semiannual monitoring HGSOC progression via TVU performs the
best (0.9% of total HGSOC curves succumb [see Table 3.1 for definitions]) despite
the frequent TVU monitoring, compared to a 4.2% succumb rate when monitored
annually, or 10.7% when monitored biannually.
It is also worth noting the relatively large proportion of HGSOC curves that
remain occult (50.9% of the total n = 1000 growth curves in this representative
simulation, see Figure 3.6). This representative simulation was performed using the
baseline parameters outlined in Tables 3.2 and 3.2.3.
3.3.5 TVU Sensitivity Analysis
We conducted a sensitivity analysis with respect to the TVU detection thresh-
olds, set at 0.5, 1 or 1.5 cm3, to determine whether the percentages reported above
would drastically vary. We demonstrate that the percentage of HGSOC growth
curves that reach the updated baseline detection and life-threatening tumor volume
thresholds in between the same monitoring events increases with less frequent TVU
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Figure 3.6: We report the relative proportions of HGSOC curves that remain occult
(first, black horizontal column), that are detectable in the first or subsequent TVU
monitoring events (second, grey horizontal column), and lastly, that are succumbed
(third, white horizontal column) out of n = 1000 initial HGSOC growth curves. The
proportions reported vary for different TVU monitoring frequencies, i.e., every 5, 4,
3, 2 years, every 1 year (annually) or every 6 months (semiannually). Importantly,
the last horizontal column represents the percentage of HGSOC growth curves that
would be missed even under frequent TVU monitoring.
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Monitoring Frequency 10 cm3 1.5 cm3 1 cm3 0.5 cm3
6 months 9 0 0 0
1 year 26 13 3 0
2 years 61 34 23 12
3 years 70 29 37 25
4 years 78 33 46 50
5 years 79 36 60 71
Table 3.5: Each table entry represents the difference between consecutive screen-
ing frequencies (e.g., 79, the leftmost entry, bottom row, represents the number of
additional HGSOC growth curves that would be missed when switching from a 4-
year monitoring frequency to a 5-year monitoring frequency) or consecutive TVU
detectability sensitivities (e.g., 36, the second leftmost entry, bottom row, represents
the number of additional HGSOC growth curves that would be missed when switching
from a 1 cm3 TVU detection threshold to a 1.5 cm3 TVU detection threshold).
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monitoring events (Figure 3.3.5, panel A), and decreases with more sensitive TVU
detection thresholds (Figure 3.3.5, panel B).
Our findings confirm that more sensitive TVU detection thresholds and more
frequent TVU monitoring improve diagnostic accuracy (decreasing the number of
succumbed HGSOC growth curves). These plots were generated from one represen-
tative simulation using a total number of n = 1000 simulated growth curves and
performed using the same baseline parameter set and cell-number-to-volume and
tumor diameters conversions as reported in Tables 3.2 and 3.2.3. The data used to
produce Figure 3.3.5 is given in Table 3.5.
3.4 Discussion of Modeling Results
HGSOC constitutes an attractive target for early detection strategies if de-
tected before reaching large volume advanced stage, when overall survival rates are
grim [109]. The validation of any HGSOC tumor volume clinical detection strategy
is thus whether frequent screening is capable of lowering mortality rates. However,
numerous transvaginal ultrasound (TVU) detection-based population studies aimed
at detecting low-volume ovarian cancer have not yielded reduced mortality rates and
thus challenge the effectiveness of TVU as a HGSOC monitoring strategy aimed at
improving overall survival rates [5, 19, 23,28,96,98,101,110–112].
A quantitative invalidation of TVU as an effective HGSOC screening strategy
is a necessary next step. Our mathematical modeling approach proposes a quanti-
tative explanation for the reported failure of TVU to improve HGSOC low-volume
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Figure 3.7: (A) Fewer HGSOC growth curves reach the succumbed status with
more frequent TVU monitoring events (x-axis) and more sensitive TVU detection
thresholds (0.5 cm3, black vertical columns; 1 cm3, dark grey vertical columns; 1.5
cm3, light grey vertical columns; 10 cm3, white vertical columns). In this panel,
vertical columns indicate the percentage of additional HGSOC growth curves that are
missed by decreasing TVU detection thresholds relative to the baseline TVU detection
threshold set at 10 cm3, out of a total of 1000 simulated HGSOC growth curves. (B)
Fewer HGSOC growth curves reach the succumbed status with more sensitive TVU
detection thresholds (x-axis) and more frequent TVU monitoring events ranging from
six months to five years. In this panel, vertical columns indicate the percentage of
additional HGSOC growth curves that are missed by decreasing the frequency of
TVU monitoring events relative to a baseline 6-month frequency, out of a total of
1000 simulated HGSOC growth curves.
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detectability and overall survival.
We develop a novel in silico mathematical assessment of the efficacy of a uni-
modal TVU monitoring regimen as a strategy aimed at detecting low-volume HG-
SOCs in cancer-positive cases; our model captures the dynamic, temporal evolution
of HGSOC progression, and is characterized by several rare rate-limiting events,
which can be associated in part with (epi)genetic alterations in tumor suppressor
genes and DNA damage repair pathways.
We chose to focus on an unimodal, ultrasound-based HGSOC detection method
(i.e., TVU), rather than on blood biomarker levels (i.e., CA125 or HE4 levels),
pelvic examinations or simultaneous TVU and CA125 detection. Despite its well-
recognized detection limitations in detecting localized or distant metastatic burden,
TVU examinations are routinely performed when assessing ovarian volume, while
the latter are either not recommended as low HGSOC volume detection unimodal
prognostic markers [5,26], or have not been shown to confer a mortality benefit [5,30].
Our results suggest that multiple frequency TVU monitoring across various
detection sensitivities does not significantly improve detection accuracy of HGSOCs
in an in silico cancer-positive population. Specifically, despite the fact that semi-
annual monitoring HGSOC progression via TVU performs, as expected, the best
compared with annual or biannual monitoring (0.9% succumbed cases versus 4.2%
and 10.7%, respectively), a nonzero percentage of succumbed cases is reported in
all subsequent simulations of the HGSOC growth and progression model.
Given that our TVU monitoring algorithm is assumed to have 100% speci-
ficity and 100% positive predictive value, the actual percentage of such succumbed
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HGSOC cases might be substantially higher. This invalidates the use of TVU as an
effective HGSOC screening strategy aimed at lowering mortality rates in general-risk
or high genetic-risk women. Our mathematical model thus represents a novel at-
tempt to explain why multiple, large-scale TVU-based HGSOC detection screening
studies have not proven significant mortality benefits, and focuses on a malignancy
that has received very little attention by the mathematical oncology community.
We find that the median time until baseline TVU detection from the inception
of the first HGSOC cell is 26.7 years. Given that an average patient’s age at diagnosis
of ovarian cancer is 55 − 65 years [4], our findings suggest that the first HGSOC cell
may appear on average around 28 - 38 years of age, during a patient’s premenopausal
period. This may be due to a number of factors, including reproductive history, oral
contraceptive use and family history of breast or ovarian cancer [113,114].
Furthermore, simulation results suggest that once a HGSOC tumor volume
becomes clinically detectable, it takes an additional median number of 1.7 years to
reach the baseline life-threatening tumor volume threshold; this implies that for a
radiographically detected, treatment-free malignancy in which no surgery and/or
systemic therapies have yet been performed/administered, the patient would suc-
cumb to the disease relatively quickly after initial diagnosis.
Since 90% of the diagnosed HGSOC patients do not have abnormal clinical
findings based on TVU performed 12 months or more prior to HGSOC diagno-
sis [101], the reported median window of opportunity interval length (1.76 years)
reflects a bias towards the more aggressive and fast-growing HGSOCs. This is a key
prediction of our model, provided by computer simulations in the absence of clini-
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cal/experimental estimates of the period of time needed to reach the life-threatening
tumor volume threshold or window of opportunity interval length.
This does not, however, translate into reduced mortality levels in an in silico
cohort across multiple TVU monitoring frequencies or detection sensitivities. Our
findings suggest that even a semiannual, unimodal TVU monitoring protocol is
expected to miss detectable HGSOCs. We also find that circa 50% of the simulated
HGSOC growth curves never reach the baseline detectability threshold, and that on
average, 57 rate-limiting events are associated with reaching HGSOC detectability
and life-threatening untreated HGSOC volumes respectively.
The predictions obtained with our HGSOC model are consistent with other
published cancer progression chronologies reported for colorectal [115] or pancre-
atic cancers [116, 117]. Yachida et al. [117] analyzed genomic sequencing data of
metastatic tumors from 7 patients with metastatic pancreatic cancer and calculated
that the first parental (non-metastatic) founder cancer cell may require 6.8 years
to generate sub-clones with metastatic potential . These sub-clones could give rise
to distant metastases within 2.7 years, with clinical diagnosis occurring 1820 years
after the genesis of the founder cell.
Jones et al. [115] also reported that a benign colorectal tumor might require
17 years to develop into an advanced carcinoma . On a larger timescale, Meza et
al. [116] reported that the average time from an initial premalignant mutation to
the ultimate conversion of a detectable cancer in pancreatic and colorectal cancers
may take up to 50 years .
While tumor progression timelines may vary for different cancers, these studies
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share the implications that a period of at least 20 years since inception of the first
malignant cell should pass before a primary tumor becomes detectable.
Our modeling results can also be correlated with published comprehensive ge-
nomic studies of clinically annotated HGSOC samples. For example, The Cancer
Genome Atlas Research Network examined 489 HGSOC tumor samples, and pro-
vided the most comprehensive and integrated catalogue of (epi)genomic changes
associated with HGSOC progression to date [118].
An outcome of our model is that an estimated 5 to 8 infrequent, rate-limiting
events associated with changes in the initial growth saturation rate, kdecay, are re-
quired to reach a baseline TVU detectable or life-threatening untreated HGSOC
tumor volume.
Additionally, we note the substantial heterogeneity in the number of such
genomic aberrations predicted by our model, and observe that on average, one or two
extra events are required in order for a detectable HGSOC tumor volume to become
life-threatening. Our modeling findings align with the reported heterogeneity and
number of the HGSOC-associated pathways altered in clinical HGSOC samples, as
identified in [118] (see Figure 3 therein).
Our mathematical modeling approach also represents a novel in silico frame-
work aimed at modeling HGSOC growth and progression. Surprisingly, few similar
mathematical modeling inferences regarding the evolution of ovarian cancers or esti-
mating the efficacy of various ovarian cancer screening strategies have been published
to date.
Durrett et al. developed a multi-type branching processes model for ovarian
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cancer growth and progression to estimate the window of opportunity for screening,
which they define as the time during which TVU-based tumor detection can result
in a significantly reduced chance of mortality [71]. Based on their mathematical
analysis, a window of opportunity of 2.9 years is predicting, implying that ovarian
cancer screening should occur at least biannually.
In another example, Brown and Palmer used a Monte Carlo method to fit an
exponential in silico model for tumor growth, with separate growth rate parameters
for early and advanced stage serous ovarian cancers [72]. The Brown and Palmer
study was based on occult tumor size data collected from healthy germline BRCA1
mutation carriers who had their ovaries and Fallopian tubes prophylactically re-
moved. They estimated the window of opportunity for TVU detection of early
stage occult serous cancers to be 4.3 years, and predicted that most serous cancers
would progress to an advanced stage a median of 0.8 years prior to clinical, surgical
detection.
Nonetheless, these existing mathematical efforts, conducted towards modeling
ovarian carcinogenesis or estimating the efficacy of various ovarian cancer screening
strategies, do not properly account for the considerable degree of heterogeneity of
the disease [57, 118] and correlate primary tumor size with metastatic potential,
disregarding clinically reported findings of low primary tumor volume advanced-
stage HGSOCs or large primary tumor volume early-stage HGSOCs [94].
In contrast, our mathematical investigation focuses specifically on model-
ing HGSOC growth and progression, and does not link primary tumor volume to
metastatic potential. Moreover, our findings show that multiple frequency TVU
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monitoring across various TVU detection sensitivities does not significantly improve
the detection of HGSOC tumor volumes in an in silico cancer-positive HGSOC pop-
ulation.
Several limiting assumptions were made in our model. First, we do not dis-
tinctly address the underlying mechanism behind either HGSOC initiation or its
progression, but it is well known that many factors may contribute to HGSOC
carcinogenesis and progression (e.g., loss of function of tumor suppressor gene p53
and the disruption of the homologous recombination repair pathway via somatic or
germline mutations of the BRCA1 and BRCA2 genes [10, 57,118]).
Second, we assume that the initiation of HGSOC occurs at some point during
a womans premenopausal stage, and we increment time in intervals of 28 days (the
average length of a menstrual cycle) to reflect subsequent potential changes in the
growth saturation rate. A clinically recognized risk factor for HGSOC progression
is the number of ovulatory events during a woman’s lifetime [73,94].
Third, we do not associate a direct cost to a more rapid cell cycle time (or
faster doubling time), even though one probably does exist in vivo. Given the model
sensitivity to initial conditions (the initial tumor growth rates), we chose conserva-
tive baseline TVU detection and life-threatening volume thresholds. Variation in
the model parameters or baseline thresholds would only result in a faster or delayed
HGSOC progression, but would not yield substantially different median or range
values for the estimated cdf’s. A reasonable parameter set range would, however,
enable us to obtain sharper estimates.
Finally, it is possible that HGSOC rates of cellular division may vary within
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different subcellular populations belonging to the tumor volume. For simplicity, we
do not distinguish between the various subpopulation growth rates, as such values
are difficult to quantify empirically.
3.4.1 Conclusions
The HGSOC growth and progression model presented here represents an ini-
tial and novel attempt to model in silico a clinically occult pathological process,
and obtain quantitative estimates of otherwise unknown statistics that are impos-
sible to obtain even in large-scale prospective cohort screening studies (i.e., the
time needed to reach baseline TVU detectability, the time needed to reach baseline
life-threatening untreated tumor volume, and the window of opportunity interval
length).
Our mathematical model provides a quantitative mathematical explanation
that supports clinical findings such as the ones reported in [101] and results from
prospective TVU screening trials such as the UKTOCS or PLCO, and thus rep-
resents a novel attempt to explain why multiple, large-scale TVU-based HGSOC
detection screening studies have not proven significant mortality benefits.
Our model is consistent with case reports and prospective TVU screening
population studies in that a key prediction of our model is that HGSOC detection
is not amenable to frequent TVU monitoring. The mathematical model provides
support to the empirical recommendation against frequent HGSOC monitoring or
screening [26].
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Chapter 4: Modeling Ovarian Cancer Cell Growth Dynamics In Vitro
in Response to Antimitotic Drug Treatment
The results in this chapter were published in [59]. It focuses on a mathemat-
ical study of ovarian cancer cellular population growth dynamics and therapeutic
administration in vitro.
4.1 Introduction to Antimitotic Therapies
Intratumoral cancer heterogeneity represents a major obstacle to improving
the overall response and survival of cancer patients [119–122]. While most tumors
initially respond well to drug therapies, many will relapse at a certain point fol-
lowing treatment [123, 124]. One of the major reasons behind therapeutic failure is
attributed to cancer cell-intrinsic factors, such as variations in cell-cycle parameters,
(e.g., cell-cycle duration, apoptosis length, mitotic index, percentage of apoptotic
cells) and the presence of quiescent cancer cells, both which decrease the efficacy of
therapies that rely on active cell-cycling [125–128].
Antimitotic cancer drugs represent a highly diverse and successful class of
antimitotic agents, reported to have a broad spectrum of potent anti-tumor activity
in various hematological and solid malignancies, including ovarian cancers [129–
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136]. Examples of such drugs include microtubule-targeting agents, e.g., taxanes and
vinca alkaloids, and newer agents that disrupt mitosis without affecting microtubule
dynamics, e.g., kinesin spindle protein inhibitors and inhibitors of mitotic kinases
[137–147].
While the primary drug target depends on the antimitotic agent used, pre-
clinical data from in vitro experiments showed that prolonged mitotic arrest occurs
in 100% of the cell populations under study irrespective of the agent used [148–152].
However, these data also revealed that while all proliferating cells will undergo mi-
totic arrest when exposed to high concentrations of antimitotic drugs, there is con-
siderable cell-to-cell variation of apoptotic response to antimitotic drugs in human
cancer cell lines.
Such observations have been reported in multiple single cell studies involving
individual cancer cells in culture in the presence of various antimitotic drugs, includ-
ing kinesin-5 inhibitors [149,151], taxol [148,150–156], and nocodazole [151,157–159].
In the presence of identical drug exposure times and concentrations, the extent of
heterogeneity in cellular response reported both within and across cancer cell lines
is considerable [148–152,154–156].
For example, in [151], the authors analyzed 15 different cancer cell lines for
their long-term response to different antimitotic drugs. They found that cellular re-
sponses to identical drugs are heterogeneous, e.g., within each distinct cell line, cells
exhibit different responses following prolonged mitotic arrest, such as undergoing
apoptosis after exiting mitosis, dying after completing several mitoses, or dying in
interphase.
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Investigating the role of intrinsic cell heterogeneity emerging from variations
in cell-cycle parameters and apoptosis in ovarian cancer cell growth dynamics in
vitro is a crucial first step towards better informing antimitotic drug administration
in the treatment of ovarian cancers.
4.1.1 Previous Work
Several mathematical models have been formulated to investigate the dynamic
variations among different cellular phenotypes and their role in the emergence of
adaptive evolution and chemotherapeutic resistance [160–164], or the impact of can-
cer cell size, age and cell-cycle phase in predicting the long-term in vitro population
growth dynamics [165–174].
For example, in [165], the authors modeled the cancer cell population dynamics
using a system of four partial differential equations (PDEs) representing the four
cell-cycle phases (i.e., G0, G1, S andM) with relative DNA content as the structuring
variable. The goal therein was to obtain the steady DNA distributions for each cell-
cycle phase, and match the flow cytometry DNA profiles of the human melanoma
NZM13 cell line at various timepoints following the addition of paclitaxel.
In [167], the authors derived two novel mathematical models, a stochastic
agent-based model and an integro-differential equation model, in order to study
the effect of cell-cycle induced intrinsic tumor heterogeneity on the overall growth
dynamics of the OVCAR-8 human ovarian carcinoma cell line. Both models char-
acterized the growth of OVCAR-8 cancer cells as dynamic interactions between the
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proliferative, quiescent and apoptotic states. The models were designed to predict
the cancer growth as a function of the intrinsic heterogeneity in the duration of
the cell-cycle and apoptosis process, and also included cellular density dependency
effects. An extension of these models to spatial models was done in [168].
4.1.2 Model Findings
In this chapter, we reformulate the models of [167]. Specifically, we assume
that cells are structured by their age, i.e., how long each cell will spend in the
cell-cycle or apoptosis. The advantages of the present approach lie in the ability
to access directly the cellular age in each compartment, and to study the impact
of prolonged mitotic arrest induced by antimitotic agents on the long-term ovarian
cancer growth dynamics. Our model comprises of two PDEs for the proliferative and
apoptotic cell compartments structured in cellular age, and one ordinary differential
equation for the quiescent compartment.
We model the prolonged mitotic arrest induced by the drug as an increase in
the average cell-cycle length duration, a consequence of the slowing or blocking of
mitosis at the metaphase-anaphase transition [149, 153, 157, 175]. We assume that
if the total time a cell spends in the cell-cycle is greater than the cell-cycle age
threshold, apoptotic cell death is triggered, a phenomenon observed in vitro [137,
149,152,153,156,157,175–181]. We use numerical simulations to subsequently study
the impact of increasing the cell-cycle length on the overall population survival.
Our results suggest that at confluence and in the absence of any drug, quies-
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cence is the long-term asymptotic behaviour emerging from the ovarian cancer cell
growth dynamics. This pattern is maintained in the presence of a small increase in
the average cell-cycle length. However, an intermediate increase in cell-cycle length
markedly decreases the total number of cancer cells present, and can drive the cell
population to extinction. A large “switch-on/switch-off” increase in the average cell-
cycle length maintains an active cell population in the long-term, with oscillating
numbers of proliferative cells and a relatively constant quiescent cell number. In-
triguingly, our results suggest a large “switch-on/switch-off” increase in the average
cell-cycle length may maintain an active cancer cell population in the long-term.
This work is aimed at understanding ovarian cancer cell growth dynamics in
the context of cancer heterogeneity emerging from variations in cell-cycle and apop-
tosis parameters. The mathematical modeling framework proposed herein merits
consideration as one of the few mathematical models to investigate dynamic can-
cer cell responses to prolonged mitotic arrest induced by antimitotic drug exposure.
Our proposed modeling framework can serve as a basis for future studies of the het-




The system (4.1)-(4.3) is a novel physiologically motivated mathematical model
that assumes continuous distributions on cellular age, i.e., the times spent in the
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cell-cycle and apoptosis process. The model consists of proliferative (i.e., cells ac-
tively dividing, in either a G1, G2, or M -like state), quiescent (i.e., a G0-like state),
and apoptotic compartments, as illustrated in Figure 4.1.
The proliferative compartment is structured by the time remaining to be spent
by cells in the cell-cycle before successfully completing mitosis and doubling. The
apoptotic compartment is structured by the time remaining for cells to fully degrade
and complete apoptosis. Accordingly, the dynamics of the cancer cell population is
governed by the following system:
∂tP (t, a)− ∂aP (t, a) = αQP (t)Q(t)fP (a)1[0,ā] − αPA(t)P (t, a), (4.1)
∂tQ(t) = 2P (t, 0)− (αQP (t) + αQA(t))Q(t), (4.2)










Initial conditions for this system are described below.
4.2.2 Model Description
In these equations, P (t, a) represents the number of proliferative cells at time
t that still spend a in this compartment before doubling. The rates of change of
P (t, a) with respect to the experimental time course t and age a are represented
by ∂t and ∂a, respectively. The term ∂aP (t, a) in Equation (4.1) implies that the
time remaining until proliferating cells complete the cell-cycle decreases as time t
advances.
When entering the cell-cycle, each cell is assigned its individual amount of time
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Figure 4.1: Proliferative cells can either transition to A or to Q at a = 0 upon com-
pletion of the cell-cycle. Quiescent cells can either transition to P with rate αQP (t),
or to A with rate αQA(t). For illustration purposes, cells within each compartment
are grouped together. The various shades of green represent the different times re-
maining to be spent by cells in the proliferative compartment (i.e., in the cell-cycle)
before transitioning. Similarly, the various shades of red represent the different times
remaining to be spent by cells in the apoptotic compartment, before completing apop-
tosis and being removed from the numerical simulations. The three explicit transition
rates (i.e., αQP (t), αPA(t), and αQA(t)) are illustrated using black arrows pointing
in the direction of the respective transition. The implicit transition from P to Q
representing the successful completion of the cell-cycle is denoted by a grey arrow.
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to be spent cycling, i.e., a, which is randomly selected from the Gaussian distribution
function with mean µ and standard deviation σ, and probability density function
fP (a). When reaching a = 0, cells in P exit the cell-cycle. The maximum length
of time spent in P before exiting thus corresponds to the maximum length of the
mitotic arrest induced by an antimitotic drug. We assume that the transition of
cells back to Q is due to a successful (i.e., non-aberrant) mitosis.
Cells in Q act as a reservoir for the other two compartments, i.e., they either
move into the apoptotic or proliferative compartment with rates αQA(t) or αQP (t),
respectively. Intuitively, quiescent cells are not actively progressing through the
cell-cycle, nor are committed to undergo apoptosis (i.e., they remain in a G0-like
state).
Cells can undergo apoptosis immediately after exiting the cell-cycle, after com-
pleting several mitoses, or during interphase. Once cells enter A, they are irreversibly
committed to completing apoptosis, and cannot transition back to either P or Q.
When apoptosis is completed, cells are removed from the numerical simulation. The
term ∂aA(t, a) in Equation (4.3) implies that the time remaining until cells complete
apoptosis decreases as time t advances.
Cells undergoing apoptosis take time to fully degrade [182,183]; until apoptosis
is completed, the cells still take up space and can inhibit the growth of neighbor-
ing cells in vitro [156, 183]. Upon entering the apoptosis compartment, the time
remaining to be spent there is randomly chosen from a probability distribution,
e.g., Gamma distribution Γ(ω, λ) with shape parameter ω, rate parameter λ, and
probability density function fA(a). The choice for this probability distribution is
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explained in greater detail in Section 4.2.5.
We note that the two age-structured PDEs for the proliferative and apoptotic
cell compartments enable us to monitor a cell’s progress through the cell-cycle (in the
case of a cell in P ), or advancement through apoptosis until complete degradation
(in the case of a cell in A).
Additionally, we assume that if, upon entering P , the time a cell will spend in
P , a, is greater than the threshold ā (i.e., the cell-cycle age threshold correspond-
ing to a prolonged mitotic arrest), the cell will undergo apoptosis, and will thus
immediately transition to A. This phenomenon has been observed in vitro when
the sustained prolonged mitotic arrest caused by antimitotic drug exposure leads
to apoptotic cell death via the gradual accumulation of cell death signals that ul-
timately trigger apoptosis. Examples include the phosphorylation and subsequent
inactivation of the anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-xL, and Mcl-1), PARP
cleavage, and the activation of caspases 3, 7, and 9 [152,153,155–157,177,184–186].
4.2.3 Initial Conditions
Initial conditions for the system (4.1)-(4.3) are as follows:
P (0, a) = 0, (4.4)
Q(0) = ρ(0)K, (4.5)
A(0, a) = 0, (4.6)
where ρ(0) represents the initial in vitro plating density. Here, three different ini-
tial conditions are used, i.e., Q(0) = 0.1 K, Q(0) = 0.45 K, and Q(0) = 0.8 K,
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corresponding to 10%, 45%, or 80% of the plating carrying capacity K, respectively,
according to experimental setup in [167]. We note that the Q(0) = 0.1 K and
0.8 K cases are identical to the initial conditions reported in [167]. For comparison
purposes, we consider in this work an intermediate case, Q(0) = 0.45 K, which
corresponds to the mean value of the two experimental datasets reported in [167].
Therein, the OVCAR-8 growth dynamics measuring total cellular density every 24
hours for a period of 96 hours in the two different seeding densities (i.e., 10% and
80% of the in vitro plating density) was subsequently recorded. For a more detailed
description of the experimental design, we refer to [167, Appendix B.1.2].
We note that Equation (4.1) does not require a boundary condition at a = 0,
since this is a PDE that models a transport process with outward flux only, i.e.,
once proliferating cells reach a = 0, they double, after which both daughter cells
return to quiescence before entering another cell-cycle.
4.2.4 Inter-compartmental Dynamics
Following [167], the OVCAR-8 transition rates that describe the processes of
mitotic exit followed by quiescence, mitotic exit or quiescence followed by the onset
of apoptosis are, respectively:













P (t), Q(t), and A(t) represent the total number of cells at time t in the prolifera-
tive, quiescent, and apoptotic compartments. Herein, the total number of prolifer-
ative and apoptotic cells are integrated over the cellular age, i.e.,
∫
P (t, a) da and∫
A(t, a) da, respectively. The total number of cells which occupy the plate at time
t is described by Ntot(t) = P (t) + Q(t) + A(t). The total number of non-apoptotic
cells at time t is described by N(t) = P (t) +Q(t). OVCAR-8 cell density is denoted
by ρ(t) = Ntot(t)/K, with K representing in vitro confluence. Here, ρ = 1 when
Ntot(t) = K implies that cells have reached confluence at time t. For a complete
explanation and derivation of the transition rates in (4.7)-(4.9) we refer to [167].
We note that the functional forms in Equations (4.7)-(4.9) are time- and
density-dependent, and reflect the in vitro experimental conditions used in [167],
where OVCAR-8 cells were seeded at different cell densities, and initially synchro-
nized to be quiescent using starvation media.
Additionally, we assume that for a given in vitro cell density at time t, there
exists an equilibrium distribution of cells actively in the cell-cycle. This is repre-
sented in the model by the function β(ρ(t)), i.e., the fraction of proliferating cells
as a function of the in vitro cell density ρ(t) at equilibrium.
Experimentally, in order to determine β(ρ(0)), in [167], OVCAR-8 human
ovarian carcinoma cells seeded at different cell densities were initially synchronized
as quiescent, using two distinct cell-cycle arrest experiments performed by changing
the starvation media and duration of the experiment. For a more detailed description
of the experimental design, we refer to [167, Appendix B.1.1].
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In the model, β(ρ(t)) is described by:
β(ρ) = βm e
−θ(ρ−ρm)2
ρ(1+ε−ρ)2 , (4.10)





A complete list of the variables and parameters used throughout the modeling
framework (4.1)-(4.10) and their interpretation can be found in Tables 4.1 and 4.2.
We note that the parameters and functional forms described above are adapted
from [167].
4.2.5 Intra-compartmental Dynamics
The age-structured mathematical model proposed above incorporates an in-
trinsic form of cell heterogeneity in the in vitro cancer cell growth dynamics, specifi-
cally in the distribution of times individual cells spend in the cell-cycle and apoptosis
process.
To the best of our knowledge, there are no in vitro studies describing the dis-
tribution of times individual OVCAR-8 cells spend in the cell-cycle. In [167], Greene
et al. chose to model the amount of time OVCAR-8 cells spend in the proliferative
compartment, P , as a normal distribution, N (µ, σ), with probability density func-
tion fP (a). In our model, the density function is re-normalized to integrate to 1 on
the interval [0,∞).
Based on the temporal OVCAR-8 growth dynamics reproduced in Figure 4
in [167], the mean cell-cycle length obtained when fitting to the experimental data
is µ = 19.12 hours, when the initial plating density is set at Q(0) = 10% of the
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Variable Value Definition
t [0, 200] (hours) Time
a [0, 80] (hours) Maximum time remaining to be spent in P or A
P (t, a) [0,∞) (cells) Number of proliferative cells at time t with time a to spend in P
Q(t) [0,∞) (cells) Number of quiescent cells at time t
A(t, a) [0,∞) (cells) Number of apoptotic cells at time t with time a to spend in A
Ntot(t) [0,∞) (cells) Total number of cells at time t
N(t) [0,∞) (cells) Total number of non-apoptotic cells at time t
fP (a) [0,∞) PDF of N (µ, σ), describing the cell-cycle length without drug
fP,c(a) [0,∞) PDF of N (µ+ c(t), σ), describing the cell-cycle length with drug
c(t) [0,∞) (hours) Drug-induced mitotic arrest extending the average cell-cycle length
fA(a) [0,∞) PDF of Γ(ω, λ) describing the length of apoptosis
ρ(t) [0,∞) In vitro cell density at time t
β(ρ(t)) [0, 1] Fraction of total number of cells in P as a function of ρ(t)
αQP (t) [0,∞) Transition rate from Q to P
αPA(t) [0,∞) Transition rate from P to A
αQA(t) [0,∞) Transition rate from Q to A
Table 4.1: List of variables used throughout the OVCAR-8 growth dynamics model.
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Parameter Value Definition
ω 4.9436 Shape parameter for the length of apoptosis
λ .19117 Rate parameter for the length of apoptosis
ā [24.23, 28.12] (hours) Cell-cycle age threshold
K 40401 (cells) In vitro carrying capacity
µ [15.23, 19.12] (hours) Mean cell-cycle length without drug
σ 3 (hours) Standard deviation of the cell-cycle length without drug
c [0.37, 0.64](hour−1) Cellular reaction rate
γ [0.0005, 0.9999] Transition probability to enter A
d 0.03 Fraction of total number of cells in A
βm [0, 1] Maximum of β(ρ(t))
ρm [0, 1] Maximizing density of β(ρ(t))
ε [0, 1] Parameter governing the shape of β(ρ(t))
Table 4.2: List of parameters used throughout the OVCAR-8 growth dynamics
model.
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maximum plating density, K. When the initial plating density is Q(0) = 80% of
the maximum plating density, K, the mean cell-cycle length obtained when fitting
to the experimental data is µ = 15.23 hours. When fitting the system (4.1)-(4.3)
to the experimental data for both plating density conditions, the mean cell-cycle
length obtained is µ = 18.33 hours. Experimentally, the doubling time reported
for OVCAR-8 cells decreases with higher plating density, and varies between 14.57
hours (see [187]) and 26.1 hours [188].
The amount of time cells spend in the apoptosis compartment, A, is assumed
to follow a Gamma distribution, Γ(ω, λ), where ω and λ denote the shape and rate
parameters, respectively, with probability density function fA(a). These parameters
are set at ω = 4.9436 and λ = 0.19117, respectively, to match the experimental
results of [182] on the length of the apoptotic process. They are identical to the
ones used in [167] to characterize this process.
We note, however, that the study of [182] investigated the individual responses
of PC12 rat adrenal gland tumor cells to serum deprivation. Therein, the authors
performed a comprehensive study on the fate of distinct cells undergoing apoptosis
following serum removal. To the best of our knowledge, no such studies performed
on human cancer cell lines have reported a distribution of the time individual cells
spend in apoptosis at a such a fine resolution, either in the absence or the presence
of antimitotic drugs. We thus chose to model the probability density function of the
length of apoptosis process based on the experimental data in [182]. The remaining
model parameters listed in Table 4.2 are obtained following the parameter estimation
procedure described in [167].
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4.2.6 Cellular Response to Antimitotic Drugs
In our model, we consider an antimitotic drug whose effect on the OVCAR-8
cellular dynamics is to induce mitotic arrest, extending the average cell-cycle length.
We assume the administered drug to be homogeneously distributed, such that all
cells in P are equally susceptible to its effect.
Specifically, the impact of the drug is to increase the time cells spend in the
proliferative compartment, P , corresponding to a sustained mitotic arrest. Upon
exiting quiescence and entering the cell-cycle, a cell can undergo one of two fates:
i) if the time chosen to be spent in P is lower than the threshold ā, the cell enters
P , progresses through the cell-cycle, and either successfully completes mitosis with
rate αQP , or undergoes apoptosis with rate αPA; ii) otherwise, the cell commits to
undergoing apoptosis, and immediately moves to the apoptotic compartment, A.
The parameter ā serves as the cell-cycle age threshold corresponding to a prolonged
mitotic arrest, after which cells exit the cell-cycle and undergo apoptosis.
It is a well-known phenomenon in vitro that a sustained mitotic arrest (i.e.,
slowing or blocking of mitosis at the metaphase-anaphase transition, thus increasing
cell-cycle length), predisposes cancer cells to undergoing apoptosis following mitotic
exit [129, 130, 137, 149, 152, 153, 155–157, 175, 186]. This was revealed using time-
lapse microscopy data, where exposure of cancer cells to saturating antimitotic drug
concentrations delayed to various extents the cells from exiting drug-induced mitotic
arrest and undergoing subsequent apoptosis.
In our model formulation, the antimitotic drug acts directly on the OVCAR-8
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cell-cycle dynamics by increasing the average cell-cycle length, and as a consequence,
causing cells to transition to the apoptotic compartment. To include the effect of
such a drug, we shift the expected value µ of the normal distribution by the function
c(t) corresponding to the cell-length increase induced by the antimitotic drug, i.e.,
fP,c(a) is the probability density function of the normal distribution N (µ+ c(t), σ).
The system (4.1)-(4.10) remains otherwise unchanged. Here, c(t) can, for example,
be modeled as a constant or bang-bang function throughout the duration of the
simulation time t = 200h, corresponding to either a sustained, constant mitotic
arrest or a switch-on/switch-off arrest.
Experimentally, the sustained, constant mitotic arrest corresponds to the large
cell-to-cell variations in the duration of mitotic arrest and the timing of drug-induced
cell death via apoptosis observed in vitro when single cells are exposed to saturating
drug concentrations using various antimitotics for prolonged periods of time, e.g.,
96 hours or more [151,152,156].
We further investigate the impact of an in silico switch-on/switch-off mitotic
arrest on the overall OVCAR-8 cancer cell growth dynamics. This type of “bang-
bang” mitotic arrest could, for example, be induced in vitro by the periodic ad-
dition and wash-off of the antimitotic drug under study, along with growth media
refreshment. In this setting, when the drug is withdrawn, proliferating cells do not
necessarily revert to the cell-cycle length assigned to them in the absence of the
drug. Rather, these cells can still undergo a period of mitotic arrest, in which the
progression through the cell-cycle can be slowed down or blocked, leading to an
increase in the cell-cycle length, after which the cell-cycle is completed and cells exit
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proliferation.
We note that our age-structured modeling framework allows us to estimate
the number of cells present in each compartment at any given time, and to tempo-
rally trace the distribution of the times remaining to be spent in the proliferative
phase during the cell-cycle or in the apoptotic phase. This framework enables us
to dynamically estimate the amount of time remaining to be spent in each of these
processes, and to track cells in their progression through each cellular phase.
4.2.7 Remarks
In [167], Greene et al. recently proposed two mathematical frameworks for
studying the role of cell density in the dynamics of the propagation of intrinsic drug
resistance: a stochastic agent-based model (ABM) and an integro-differential equa-
tion (IDE) model, each describing the growth of cancer cells as dynamic transitions
between the proliferative, quiescent and apoptotic states.
These models incorporated an intrinsic form of cellular heterogeneity in the
durations of the cell-cycle and the apoptosis process. They were designed to predict
the cancer cell growth as a function of the intrinsic heterogeneity in the durations
of the cell-cycle and the apoptosis process, and included cellular plating density
dependencies. Model parameters were estimated in [167] using experimental data
collected from the OVCAR-8 cell line (i.e., in vitro growth rate, cell density and
apoptosis fraction measurements).
For example, in the IDE model, the dynamics of the proliferative (Np), quies-
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cent (Nq), and apoptotic (Na) compartments, respectively, are governed by:
d
dt







































Here, αp, αap , and αaq represent the transition rates between compartments. The
exact formulation of these transition rates was described in Section 4.2.4. The factor
of 2 on the right hand side of Equation (4.12) denotes a successful mitosis, where a
mother cell in the proliferative compartment completes the cell-cycle, and 2 daughter
cells enter the quiescent compartment.
Additionally, µ and σ are the mean and standard deviation of the cell-cycle
length, assumed to be a normally distributed random variable with corresponding
probability density function fp(·). Apoptosis is assumed to vary according to a fixed
Gamma distribution with the density function fa(·), following the experimental data
from [182].
By examining the role the parameters played in the evolution of the intrinsic
tumor heterogeneity in the absence of any drug, the authors concluded that the
distribution in the cell-cycle length has the most significant contribution to the
cancer growth dynamics.
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The models of [167] were extended in [168] to include different initial geomet-
ric seeding arrangements of OVCAR-8 cells exposed to paclitaxel, an antimitotic
drug, in order to investigate and quantify the spatiotemporal density of cancer cells.
The spatiotemporal differences in cancer cell growth rates, and proportions of pro-
liferative and apoptotic cells were shown to influence the evolution of intratumoral
heterogeneity under anti-mitotic drug exposure. The effects of paclitaxel on the can-
cer cell growth dynamics were quantified, based on a stochastic ABM framework.
Therein, the authors assumed cell movement could be described by a stochastic
differential equation, which took into account attractive and repulsive forces between
cells. Additionally, transitions between the proliferative, quiescent, and apoptotic
compartments were also included in the model. By keeping the global plating cell
density constant, Greene et al. concluded that cell movement and local plating
conditions are responsible for the significant differences in cancer cell proliferation
and paclitaxel-induced apoptosis rates across the different seeding arrangements.
We note that the IDE model presented in [167] represents a sophisticated con-
tinuum mathematical formulation that enabled the authors to estimate the expected
values of the number of cells in time in each of the three cellular compartments, i.e.,
proliferative, quiescent and apoptotic. Their IDE modeling results are based on the
ability to provide accurate approximation of the stochastic ABM dynamics, using
the individual ABM realizations. Their numerical simulations thus demonstrated
that the IDE is able to faithfully describe the cellular dynamics of the ABM, and
that given a wide range of model parameters, the results obtained from both models
fit the OVCAR-8 experimental data.
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The age-structured mathematical model we propose here is a novel alterna-
tive to the ABM and IDE models previously published in [167, 168]. The intrinsic
heterogeneity in time cells spend in these compartments governs the population
growth dynamics and dictates the response to anti-mitotic therapy. Using an age-
structured modeling framework allows us to estimate the number of cells present
in each compartment at any time, and to temporally trace the distribution of the
times remaining to be spent in the proliferative phase during the cell-cycle or in the
apoptotic phase.
In contrast, this information was not accessible in the IDE model, as the
only quantities that were followed over time were the total number of cells in each
compartment. This information could have been obtained from the ABM, but had
to be extracted from the multiple individual agents, and hence was not amendable
to optimization or other algorithms that function better with continuous densities
and variables. The age-structured framework enables us to dynamically estimate
the amount of time remaining to be spent in each of these processes, and to track
cells in their progression through each cellular phase.
4.3 Numerical Results
4.3.1 Cancer Cell Growth Dynamics in the Absence of the Drug
We illustrate in Figure 4.2 the OVCAR-8 cancer cell growth dynamics modeled
by the system (4.1)-(4.3), with transition rates (4.7)-(4.9), and initial conditions
(4.4)-(4.6). Specifically, we consider three sets of initial conditions, i.e., Q(0) =
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0.1 K in Figures 4.2(a), 4.2(d), and 4.2(g), Q(0) = 0.45 K in Figures 4.2(b),
4.2(e), and 4.2(h), and Q(0) = 0.8 K in Figures 4.2(c), 4.2(f), and 4.2(i),
corresponding to 10%, 45%, or 80% of the plating carrying capacity, K, respectively.
The initial plating density, with all cells being experimentally synchronized
as quiescent (described in Section 4.2.3) substantially alters the overall growth dy-
namics throughout the simulation time. This can be observed in the relative and
absolute numbers of proliferating cells (solid green line), or quiescent cells (solid blue
line), and in the total number of cells, i.e., proliferating and quiescent cells (solid
magenta line).
In the Q(0) = 0.1 K case, the ratio Q/P = Q(t)∫
P (t,a) da
(henceforth referred to
as Q/P ) is greater than 1 until around t = 2 hours, after which it becomes smaller
than 1 until around t = 63 hours. Afterwards, the ratio Q/P increases with time.
In the Q(0) = 0.45 K case, the ratio Q/P becomes less than 1 only for a brief
period of time, t ∈ [7, 13], after which it continues to increase with time. In the
Q(0) = 0.8 K case, the number of quiescent cells only decreases for a brief period of
time, t ∈ [0, 11], after which the number of quiescent cells continues to increase until
almost reaching carrying capacity. The ratio Q/P remains higher than 1 throughout
the duration of the simulation.
For comparison purposes, we also illustrate the distribution of the times re-
maining to be spent in the proliferative (P), or apoptotic (A) compartment at the
end of simulation time (t = 200 hours), for each of the initial plating densities:
Q(0) = 0.1 K in Figure 4.2(g), Q = 0.45 K in Figure 4.2(h), and Q(0) = 0.8 K
in Figure 4.2(i). The solid green lines correspond to the distribution of the time
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Figure 4.2: Numerical solutions for the system (4.1)-(4.3) in the absence of the drug
with (a)-(d)-(g) Q(0) = 10%, (b)-(e)-(h) Q(0) = 45%, and (c)-(f)-(i) Q(0) = 80% of
the in vitro carrying capacity, K. Panels (a), (b), and (c) show the dynamics of
the proliferating (P), quiescent (Q), and the total number of non-apoptotic cells (N).
Panels (d), (e), and (f) show the dynamics of the apoptotic cells (A). Panels (g), (h),
and (i) illustrate the distribution of the times remaining to be spent by cells in the
proliferative (P ) and apoptotic (A) compartments as seen at the end of the simulation
time, t = 200 hours, with (g) Q(0) = 10%, (h) Q(0) = 45%, and (i) Q(0) = 80% of
plating carrying capacity, K.
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remaining to be spent by cells in P , and the solid red lines to the times remaining
to be spent by cells in A.
In each of the three scenarios, all cells are synchronized to be quiescent at the
start of the simulation time t = 0 hours. The long-term dynamics of the system
(4.1)-(4.3) reveals that the majority of OVCAR-8 cells are quiescent at the end of
the simulation time t = 200 hours, with Ntot(t) close to the carrying capacity. There
are few remaining proliferating cells, suggesting that once cells approach confluence,
proliferation will be inhibited. The initial plating density does not alter the quan-
titative nor qualitative dynamics of the apoptotic cell compartment throughout the
simulation time (solid red lines). We conclude that at confluence and in the absence
of the drug, quiescence is the long-term asymptotic behaviour emerging from the
OVCAR-8 cancer cell growth dynamics.
4.3.2 Cancer Cell Growth Dynamics under Antimitotic Drug Action
We now investigate the dynamic behavior of the system (4.1)-(4.3) using two
distinct antimitotic drug effects, i.e., a sustained, constant mitotic arrest and a
switch-on/switch-off arrest, with three different levels of increase in the average
cell-cycle length.
In the numerical simulations depicted below, the function c(t), corresponding
to the drug-induced mitotic arrest extending the average cell-cycle length, can take
two functional forms: it is set to be a constant function c(t) = carrest set at either 2,
10, or 20 hours (solid lines); or a bang-bang function c(t) = 2carrest for 0 ≤ t ≤ 2,
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and c(t) = 0 for 2 ≤ t ≤ 4 hours, repeated periodically with period 4 until t = 200
hours (dashed lines).
4.3.2.1 Cancer Cell Growth Dynamics Given Small Increases in Cell-
cycle Length
We study the cancer cell growth dynamics given the action of the drug as
modeled by the system (4.1)-(4.3), with initial conditions (4.4)-(4.6).
To begin with, we consider small increases in the average cell-cycle length
setting carrest = 2 hours. There is a relatively small difference between the two
distinct antimitotic drug effects, see Figure 4.3 (solid versus dashed lines for each
color representing the different cellular compartments). Therein, panels (a), (b),
and (c) show the dynamics of the proliferating (P), quiescent (Q), and the total
number of non-apoptotic cells (N). Panels (d), (e), and (f) show the dynamics of
the apoptotic cells (A). Panels (g), (h), and (i) illustrate the distribution of the
times remaining to be spent by cells in the proliferative (P ) and apoptotic (A)
compartments as seen at the end of the simulation time, t = 200 hours, with (g)
Q(0) = 10%, (h) Q(0) = 45%, and (i) Q(0) = 80% of plating carrying capacity, K.
Specifically, in both cases, the number of proliferative cells, i.e., solid and
dashed green lines in Figure 4.3(a), initially increases then starts to decrease at
around t = 73 hours. The number of quiescent cells, i.e., solid and dashed blue
lines in Figure 4.3(a), initially decreases, and continues to oscillate until around
t = 40 hours, when it begins to increase with time. These oscillations are due to the
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Figure 4.3: Numerical solutions for the system (4.1)-(4.3) given small increases in
the average cell-cycle length with (a)-(d)-(g) Q(0) = 10%, (b)-(e)-(h) Q(0) = 45%,
and (c)-(f)-(i) Q(0) = 80% of the in vitro carrying capacity, K. The cellular dynamics
in each compartment given a sustained, constant mitotic arrest or a switch-on/switch-
off arrest is illustrated using solid or dashed lines, respectively.
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transitions from Q to P and back to Q. Initially, the ratio Q/P becomes less than
1 (t ∈ [2, 73]), after which it steadily increases beyond 1 throughout the rest of the
simulation time.
The total number of apoptotic cells integrated over the cellular age,
∫
A(t, a) da,
i.e., solid and dashed red lines in Figure 4.3(d), steadily increases with respect to
time. In Figure 4.3(g), we show the distribution of the times remaining to be spent
by proliferating cells (green lines), and apoptotic cells (red lines) at the end of simu-
lated time t = 200 hours given small increases in average cell-cycle length, using the
the sustained, constant mitotic arrest (solid lines) and switch-on/switch-off arrest
(dashed lines).
The two antimitotic drug effects have no noticeable difference with regards
to the cellular dynamics in either of the three compartments. Compared with the
cancer cell growth dynamics in the absence of the drug (see Figures 4.2 and 4.3),
the ratio Q/P becomes greater than 1 and subsequently increases at a slightly later
timepoint, i.e., at around t = 73 versus t = 63 hours in the absence of the drug.
Similar results are obtained when considering Q(0) = 0.45 K (see Figures
4.3(b), 4.3(e), and 4.3(h)), and when considering Q(0) = 0.8 K (see Figures 4.3(c),
4.3(f), and 4.3(i)). We conclude that nearing confluence and in the presence of
small increases in average cell-cycle length, quiescence emerges as the long-term
asymptotic behaviour resulting from the cancer cell growth dynamics.
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4.3.2.2 Cancer Cell Growth Dynamics Given Intermediate Increases
in Cell-cycle Length
We now consider intermediate increases in the average cell-cycle length, setting
carrest = 10 hours. Results are shown in Figure 4.4. Therein, panels (a), (b), and (c)
show the dynamics of the proliferating (P), quiescent (Q), and the total number of
non-apoptotic cells (N). Panels (d), (e), and (f) show the dynamics of the apoptotic
cells (A). Panels (g), (h), and (i) illustrate the distribution of the times remaining
to be spent by cells in the proliferative (P ) and apoptotic (A) compartments as
seen at the end of the simulation time, t = 200 hours, with (g) Q(0) = 10%, (h)
Q(0) = 45%, and (i) Q(0) = 80% of the plate carrying capacity, K.
The case Q(0) = 0.1 K is illustrated in Figures 4.4(a), 4.4(d), and 4.4(g).
Specifically, the number of proliferative cells (solid and dashed green lines) fluctuates
significantly at the beginning of the numerical simulation for both antimitotic drug
effects considered. However, at around t = 77.5 hours, the number of proliferative
cells exposed to the sustained, constant mitotic arrest starts to decrease with time.
The number of proliferative cells exposed to the switch-on/switch-off arrest oscillate
slightly around the number of quiescent cells.
After the initial decrease in absolute numbers at around t = 15 hours, the
quiescent cells exposed to the sustained, constant mitotic arrest exhibit a pattern of
damped oscillations. They continue to slightly decrease in numbers throughout sim-
ulation time (solid blue line). The quiescent cells exposed to the switch-on/switch-off
arrest seem to have reached a steady state at around t = 88 hours. Interestingly, for
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Figure 4.4: Numerical solutions for the system (4.1)-(4.3) given intermediate in-
creases in the average cell-cycle length with (a)-(d)-(g) Q(0) = 10%, (b)-(e)-(h)
Q(0) = 45%, and (c)-(f)-(i) Q(0) = 80% of the in vitro carrying capacity, K. The
cellular dynamics in each compartment given a sustained, constant mitotic arrest or
a switch-on/switch-off arrest is illustrated using solid or dashed lines, respectively.
88
the sustained, constant mitotic arrest, the ratio Q/P becomes greater than 1 and
increases slightly with time starting at around t = 78 hours.
However, for the switch-on/switch-off arrest, the same ratio remains consis-
tently around 1 throughout simulation time, suggesting the existence of a steady
state equilibrium between the proliferative and quiescent populations. A similar
pattern can be observed in the dynamics of the total number of proliferating and
quiescent cells (solid and dashed magenta lines).
The total number of apoptotic cells (solid and dashed red lines in Figure 4.4(d))
oscillates with time. Figure 4.4(g) shows the distribution of the times remaining to
be spent by proliferating cells (green lines), and by apoptotic cells (red lines) at
t = 200 hours. Similar results are obtained when considering Q(0) = 0.45 K, see
Figures 4.4(b), 4.4(e), and 4.4(h).
However, for Q(0) = 0.8 K, the dynamics of the proliferative (green lines),
quiescent (blue lines), and apoptotic (red lines) cell compartments are quantita-
tively and qualitatively distinct between the two distinct antimitotic drug effects,
see Figures 4.4(c), 4.4(f), and 4.4(i).
Specifically, the number of proliferative cells, i.e., solid green line in Figure
4.4(c), in the sustained, constant mitotic arrest case starts to decrease around t = 50
hours. Given the switch-on/switch-off arrest however, the number of proliferative
cells oscillates slightly (dashed green line) starting around t = 20 hours, and contin-
ues until the end of the simulated time. The number of quiescent cells (dashed green
and blue lines, respectively) continues to steadily decrease for both antimitotic drug
effects, with the quiescent cells decaying at a faster rate in the sustained arrest case
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than in the switch-on/switch-off one, see Figure 4.4(c).
A similar pattern can be observed in the dynamics of the total number of cells
(proliferating and quiescent), as represented by the solid and dashed magenta lines
in Figure 4.4(c). The total number of apoptotic cells, i.e., solid and dashed red
lines in Figure 4.4(f), starts to decrease at around t = 18 hours. In Figure 4.4(i),
we show the distribution of the times remaining to be spent by proliferating cells
(green lines), and apoptotic cells (red lines) at t = 200 hours.
The two antimitotic drug effects at intermediate increases in cell-cycle length
have a marked distinct impact on the cellular dynamics in each of the three cellular
compartments for the Q(0) = 0.8 K case. Specifically, the number of quiescent cells
decreases in time, and implicitly, the total number of cells decreases at a slower
(dashed magenta line) or faster rate (solid magenta line).
The dynamics of the cell population illustrated in Figure 4.4(c) is overall sub-
stantially different from the oscillatory dynamics observed in the Q(0) = 0.45 K
and Q(0) = 0.1 K cases. We conclude that in the presence of intermediate increases
in the cell-cycle length, the sustained, constant mitotic arrest markedly decreases
the total number of cancer cells present. A switch-on/switch-off arrest maintains an
active cell population in the long-term, with proliferative cell numbers exhibiting a
steady oscillatory state, and quiescent cell numbers remaining relatively constant in
time.
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4.3.2.3 Cancer Cell Growth Dynamics Given Large Increases in Cell-
cycle Length
We now consider increases in the average cell-cycle length, setting carrest = 20
hours. Results are shown in Figure 4.5. Therein, panels (a)-(f) show the dynamics
of the proliferating (P), quiescent (Q), and the total number of non-apoptotic cells
(N). Panels (g), (h), and (i) show the dynamics of the apoptotic cells (A). Panels
(j), (k), and (l) illustrate the distribution of the times remaining to be spent by
cells in the proliferative (P ) and apoptotic (A) compartments as seen at the end of
the simulation time, t = 200 hours, with (j) Q(0) = 10%, (k) Q(0) = 45%, and (l)
Q(0) = 80% of the plate carrying capacity, K.
When the initial density is low (Q(0) = 0.1 K), the number of proliferative
cells given the sustained, constant mitotic arrest case (solid green line in Figure
4.5(a)) remains essentially zero for the entire simulation. Given the large increase
in the average cell-cycle length induced by the drug, any cells that transition from
Q to P subsequently transition to A, instead doubling successfully at the end of the
cell-cycle.
However, given the switch-on/switch-off arrest, see dashed green line in Figure
4.5(a), proliferative cell numbers exhibit a steady oscillatory state throughout the
duration of the simulated time. The ratio Q/P oscillates around 1 as time increases
for the duration of simulation. A similar pattern can be observed in the dynamics
of the total number of cells (proliferating and quiescent), as shown by the magenta
lines in Figure 4.5(d).
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Figure 4.5: Numerical solutions for the system (4.1)-(4.3) given large increases in the
average cell-cycle length with (a)-(d)-(g)-(j) Q(0) = 10%, (b)-(e)-(h)-(k) Q(0) = 45%,
and (c)-(f)-(i)-(l) Q(0) = 80% of the in vitro carrying capacity, K.
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The total number of apoptotic cells, i.e., solid and dashed red lines in Figure
4.5(g), oscillates with time. In Figure 4.5(j), we show the distribution of times
remaining to be spent by proliferating cells (green lines), and apoptotic cells (red
lines) at t = 200 hours.
Our numerical simulations suggest that in the presence of a sustained, constant
mitotic arrest, the cancer cell population is nearly driven to extinction, see solid lines
in Figures 4.5(a) and 4.5(d). Intriguingly, in the presence of a long-term switch-
on/switch-off arrest, it is possible to maintain an active cancer cell population even
when starting with a small initial plating density (Q(0) = 0.1 K) and large increase
in the average cell-cycle length.
The balance between the quiescent and proliferative cell-turnover is maintained
over time, see dashed lines in Figures 4.5(a) and 4.5(d). Similar results are obtained
when considering Q(0) = 0.45 K, shown in Figures 4.5(b), 4.5(e), 4.5(h), and 4.5(k).
However, when Q(0) = 0.8 K, the dynamics of the proliferative (green lines),
quiescent (blue lines), and apoptotic (red lines) cell compartments are quantitatively
and qualitatively distinct between the two antimitotic drug effects, with a clear
difference between the sustained, constant and switch-on/switch-off mitotic arrest,
see Figures 4.5(c), 4.5(f), 4.5(i), and 4.5(l) (solid versus dashed lines for each color
representing the different cellular compartments).
Specifically, the number of proliferative cells given the sustained, constant
mitotic arrest, i.e., solid green line in Figure 4.5(c), remains essentially zero for
the entire simulation, similar to the 10% and 45% initial density cases. However,
given the switch-on/switch-off mitotic arrest, i.e., dashed green line in Figure 4.5(c),
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proliferative cell numbers exhibit a steady oscillatory state throughout the duration
of the simulation.
The number of quiescent cells (dashed green and blue lines, respectively) con-
tinues to steadily decrease for both drug effects, with quiescent cells decaying at a
faster rate in the sustained, constant arrest case than in the switch-on/switch-off
one, see Figure 4.5(c). A similar pattern can be observed in the dynamics of the
total number of cells (proliferating and quiescent), as represented by the solid and
dashed magenta lines in Figure 4.5(f). The total number of apoptotic cells, i.e.,
solid and dashed red lines in Figure 4.5(i), oscillates with time.
Our numerical simulations suggest that in the presence of a large sustained
increase in the average cell-cycle length induced by the drug, the cancer cell pop-
ulation is nearly driven to extinction, despite the large initial starting density, see
solid lines in Figures 4.5(c) and 4.5(f). Conversely, in the presence of a long-term
switch-on/switch-off arrest, it is possible to maintain an active cancer cell popula-
tion even when starting with a large initial plating density (Q(0) = 0.8 K) and a
large increase in the average cell-cycle length.
The dynamic balance between the quiescent and proliferative cell-turnover is
maintained over time, see dashed lines in Figures 4.5(c) and 4.5(f). We conclude
that in the presence of large increases in the average cell-cycle length induced by the
drug, a sustained, constant mitotic arrest drives both the proliferating and quiescent
cell numbers to extinction. A switch-on/switch-off arrest maintains an active cell
population in the long-term, with proliferative and quiescent cell numbers exhibiting
a steady oscillatory state in time.
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4.4 Discussion of Modeling Results
The dynamics of cellular response to antimitotic drug exposure has only re-
cently begun to be investigated in vitro using time-lapse microscopy on single cells
in culture [137,148,149,151–157,175,177,184,185].
Several studies have demonstrated that antimitotic drugs characteristically
induce a period of prolonged mitotic arrest (that can last for as long as 72 hours
or more) followed predominantly by cell death via apoptosis [151]. As such, mi-
totic arrest constitutes the first cellular response to antimitotic drug exposure, but
the mechanisms behind the drug-induced prolonged mitotic arrest and subsequent
cancer cell death remain, however, unclear [149–152,154–156,184,185,189].
To investigate this issue, multiple antimitotic drugs and different drug concen-
trations have been used in cancer cell studies. Accordingly, multiple in vitro single
cell live imaging studies have demonstrated that cancer cells display widely varying
responses to antimitotic drugs given different exposure times and drug concentra-
tions [149–152,154–156,175,184,185,189]. These findings provided strong evidence
that the duration of the mitotic arrest is not identical for all cells, both across and
within distinct cancer cell lines, in the presence of various antimitotic drugs such as
nocodazole, Kinesin-5 (Eg5) inhibitors, monastrol, or taxol [148–151,154,155].
Even within identical types of cell cultures or drugs used, cells exhibit a con-
siderable degree of heterogeneity in response to prolonged antimitotic drug expo-
sure. For example, cells may either exit mitosis and remain in interphase for an
indefinite period of time, undergo programmed cell death, (i.e., apoptosis) after
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exiting mitosis or interphase, or proceed through mitosis via multipolar spindle for-
mation [148, 150–152, 154–156, 189]. In the case of multipolar spindle formation,
cells divide into daughter cells by segregating their chromosomes in more than two
different directions, dying during the second mitosis, or remaining in interphase for
the duration of the experiments [152,189,190].
Motivated by these experimental findings, we introduce a novel mathematical
modeling framework of OVCAR-8 cancer cell dynamics given drug exposure that
incorporates an intrinsic form of heterogeneity in response to prolonged antimitotic
drug exposure via the duration of times cells spend in the cell-cycle and apoptosis
process. The system (4.1)-(4.3) is an age-structured physiologically motivated mod-
eling framework for describing in vitro cancer cell growth dynamics given a drug
that induces mitotic arrest, thus extending the average cell-cycle length.
To reflect the intrinsic cell heterogeneity, cells in the proliferative and in the
apoptotic compartment are structured by the amount of time they spend in each
phase. Herein, we considered a drug that extends the average cell-cycle length, and
studied its impact on the long-term cancer cell growth dynamics and response to an-
timitotic drug exposure using two distinct antimitotic drug effects, i.e., a sustained,
constant mitotic arrest and a switch-on/switch-off arrest, and three different levels
of increase in the average cell-cycle lengths.
Our numerical simulations suggest that at confluence and in the absence of any
drug, quiescence is the long-term asymptotic behaviour emerging from the cancer
cell growth dynamics. Upon drug addition, the cancer cell dynamics significantly
changes. Specifically, the prolonged mitotic arrest induced by the antimitotic drug
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results in a strong growth-inhibitory activity in vitro in a time-dependent manner.
In the presence of small increases in the average cell-cycle length, quiescence
emerges as the long-term asymptotic behaviour resulting from the cancer cell growth
dynamics. Our numerical simulations suggest that quiescence can emerge relatively
quickly, and can thus constitute an intrinsic resistance mechanism to antimitotic
drug exposure. The small increases in the average cell-cycle length result in a period
of slowing-down of the cell-cycle from which cancer cells can recover and continue
proliferating until reaching confluence.
From a therapeutic point of view, the presence of quiescent cancer cells has
serious implications for chemotherapy regimens, which rely on active cell-cycling to
target and kill proliferating cells. The long-term maintenance of a quiescent cancer
cell population acts as a reservoir for proliferating cells, and can ultimately lead to
cancer recurrence and shorter disease-free survival periods [125–127,191,192].
However, in the presence of intermediate increases in the average cell-cycle
length, a sustained, constant mitotic arrest markedly decreases the total number
of cancer cells present, and can drive the cell population to extinction. A switch-
on/switch-off arrest maintains an active cell population in the long-term, with prolif-
erative cell numbers exhibiting a steady oscillatory state, and quiescent cell numbers
remaining relatively constant in time.
The transient behavior in the cancer cell growth dynamics signals the emer-
gence and maintenance of a steady quiescent cell population, which in turn, rep-
resents a form of intrinsic, non-genetic resistance that results from variations in
cell-cycle parameters [193, 194]. This can potentially decrease the efficacy of ther-
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apies that rely on active cell-cycling for their killing effects, such as traditional
chemotherapies [195–197].
Moreover, given large increases in the average cell-cycle length induced by
antimitotics, cells do not resume proliferation, and are driven to extinction by a
sustained, constant mitotic arrest. Intriguingly, a switch-on/switch-off arrest may
maintain an active cancer cell population in the long-term. This suggests that unless
exposed to saturating drug concentrations for prolonged periods of time, cancer cells
may not experience a mitotic arrest for long enough in order to trigger apoptosis,
which may have therapeutic implications as clinical responses depends on apoptosis
rates, and not exclusively on mitotic arrest [137,189].
Additionally, the fate of cells following drug treatment also depends on the
cell type. For instance, cell lines sensitive to mitotic cell death tend to reach the
MOMP threshold before cyclin B1 levels reach the threshold required for cells to slip
out of mitosis [148,151,152,154,156,189]. Conversely, cell lines resistant to mitotic
cell death tend to have a faster rate of cyclin B1 degradation and/or slow rate of
intrinsic cell death activation [153,155,157,177].
These molecular-based variations in sensitivity to apoptosis and mitotic arrest
are likely to substantially contribute to the observed heterogeneity in cell responses,




The fate of cells following drug treatment may depend on the drug concentra-
tions and on the drug exposure times [148, 151, 152, 154, 156, 189]. The prolonged
mitotic arrest induced by anti-mitotic drugs (i.e., an increased period of time spent
in the cell-cycle) can lead to gradual accumulation of cell death signals that ulti-
mately trigger apoptosis in cancer cell cultures [153,155,157,177]. Investigating the
role of intrinsic cell heterogeneity emerging from variations in cell-cycle parameters
and apoptosis is thus a crucial step towards better informing drug administration
in the treatment of ovarian cancer.
In this work, we investigated OVCAR-8 growth dynamics under the effect of a
drug that extends the average cell-cycle length, and studied its impact on the long-
term cancer cell growth dynamics and response to antimitotic drug exposure. We
used two distinct antimitotic drug effects, i.e., a sustained, constant mitotic arrest
and a switch-on/switch-off arrest, and three different levels of increase in the average
cell-cycle lengths. Intrguingly, our results suggest that the transient behavior in the
cancer cell growth dynamics signals the emergence and maintenance of a steady
quiescent cell population, which in turn, represents a form of intrinsic, non-genetic
resistance that results from variations in cell-cycle parameters [193, 194]. This can
potentially decrease the efficacy of therapies for ovarian cancer that rely on active
cell-cycling for their killing effects.
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Chapter 5: Modeling Single Cell Heterogeneity in Response to Dis-
tinct Antimitotic Therapies
The results in this chapter were submitted for publication [60]. It focuses
on a mathematical study of cell fate kinetics in response to prolonged exposure to
antimitotic drugs in vitro.
5.1 Introduction to Cellular Heterogeneity in Response to Prolonged
Antimitotics Exposure
Classic microtubule-targeting drugs such as taxanes and vinca alkaloids consti-
tute a highly successful class of antimitotic drugs, with potent anti-tumor activity in
many human solid tumors, including ovarian cancers [140,147,186,190]. In an effort
to reduce the hematological and neuronal toxicity induced by these drugs and thus
improve efficacy-to-toxicity ratios, newer antimitotic drugs such as spindle-targeting
agents were recently developed.
However, these agents demonstrated limited anti-tumor activity in the clinic
[198–206]. Despite their distinct primary targets, antimitotic drugs disrupt mitotic
spindle assembly, activating the spindle assembly checkpoint (SAC), and leading to
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a prolonged mitotic arrest in 100% of the in vitro cells in the study irrespective of
the antimitotic drug used [151].
Following prolonged mitotic arrest, cancer cells predominantly undergo one
of two fates: death in mitosis via intrinsic apoptosis, or slippage out of mitotic
arrest following the gradual proteolysis of cyclin B1 and subsequent survival in a
G1 state [181,207–209].
The proportion of cells that undergo each alternative fate and the timing of
these events vary significantly between different drugs and cell types [137, 148, 149,
151, 154, 202, 207]. Even within identical types of cell cultures or drugs used, cells
treated with antimitotics exhibit a considerable degree of heterogeneity in response
to prolonged drug exposure [203,208,210]. Such observations have been reported in
multiple single cell studies involving individual cancer cells in culture in the presence
of various antimitotic drugs, including paclitaxel and Eg5 kinesin inhibitors.
Additionally, it has been experimentally demonstrated that even though the
death in mitosis and mitotic slippage pathways are simultaneously active, they func-
tion independently of each other during mitotic arrest [149,153,157]. These studies
confirmed Gascoigne and Taylor’s proposed “competing pathways model”, where
the death in mitosis and mitotic slippage pathways are hypothesized to be com-
peting against each other (i.e., the fastest process to execute in an individual cell
wins) [151].
The first pathway consists of the activation of cell death pathways, where
caspase-dependent cell death signals become stronger in time, simultaneously as cy-
clin B1 degrades [149–151,155,156,158,159,181,208,210–213]. The second pathway
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involves cells that exit mitosis following a prolonged mitotic arrest, when cyclin B1
is slowly degraded and Cyclin-dependent kinase-1 (Cdk1) activity levels fall below
the threshold needed to keep cells in mitosis and thus trigger mitotic exit, despite
continued SAC signaling [156,158,184,185,190,208,211,214,215].
For example, in the case of Gascoigne and Taylors in vitro results on the colon
carcinoma RKO cell line, the competing networks model would suggest that cell
death signals in RKO cells accumulate faster than cyclin B1 levels degrade, though
not at the same constant rate, as the different durations of mitotic arrest that RKO
cells exhibit would suggest [151]. To the best of our knowledge, no such similar
studies have been, to date, performed on human ovarian cancer cell lines.
Thus, we chose to focus on the experimental results of [151] in order to better
understand the effects of antimitotic therapy (which is a primary treatment modality
for ovarian cancer patients) on individual cancer cells.
The quantitative understanding of the cellular apoptosis and slippage rates
and their dependency on the length of mitotic arrest is essential in order to decode
and better understand the effect of the molecular mechanisms that govern cellular
fate in response to antimitotic therapy. Furthermore, it remains to be elucidated
whether any common features in the cellular responses to the different antimitotics
characterizing each pathway exist both in cell culture studies and in the clinic [137,
186,190,216,217]
We propose a quantitative description of the kinetics of colon carcinoma RKO
cells in response to the microtubule-targeting agents nocodazole and taxol, and the
spindle-targeting Eg5 inhibitors AZ138 and monastrol. Our mathematical model is
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calibrated using the in vitro observations of [151], wherein time-lapse microscopy
data demonstrated prolonged and variable durations of mitotic arrest in RKO cells
prior to subsequent cell death or slippage.
Our aim is to provide a quantitative perspective on the kinetics behind the
variability in RKO cell drug responses to distinct antimitotic drugs. We hypothesize
that the death in mitosis and mitotic slippage pathways exhibit differential kinetic
cellular apoptosis and slippage rates depending on the length of mitotic arrest.
Our mathematical model is the first study of its kind to provide the cellular
apoptosis and slippage rates and their dependency on the length of mitotic arrest
for the death in mitosis and mitotic slippage pathways in the RKO cell line. We
demonstrate numerically that these rates increase with the duration of mitotic arrest.
Additionally, given that the cellular fate is known, the hazard rates are iden-
tical among the different antimitotic drugs. This result is based on a previously
unrecognized fact emerging from our quantitative analysis, i.e., that the propor-
tions of RKO cells that survive until time “a” in mitotic arrest and subsequently
undergo death in mitosis and mitotic slippage are identical when cells are exposed
to non-taxol drugs. Moreover, we demonstrate that RKO cells display a higher haz-
ard of undergoing death in mitosis than mitotic slippage throughout the 72-hour
experimental time-course.
Overall, our results indicate that RKO cells exhibit a triphasic response curve
irrespective of cell fate or antimitotic drug. Interestingly, our quantitative analysis
suggests that the taxol-treated RKO cells display the slowest cell death in mitosis
responses across all antimitotic drugs. Despite taxol being the slowest inducer of cell
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death in mitosis in the RKO cell line as evidenced by its specific hazard function, it
turns out that its slow induction of cell death is not a good measure for predicting
its likelihood to induce death in mitosis, as 98% of RKO cells exposed to taxol do
undergo death in mitosis following a prolonged mitotic arrest. Further investigations
are needed to establish whether this is a concentration-dependent effect.
Based on these results, we formulate hypotheses on the dynamics behind the
death in mitosis and mitotic slippage pathways in RKO cells. These could potentially
expand our understanding of the mechanisms which dictate whether a cell dies or
survives a prolonged mitotic arrest, if tested in more focused experiments.
5.1.1 Model Findings
Both classic and newer antimitotics commonly induce a prolonged mitotic
arrest in cell culture. As first hypothesized and demonstrated by [151], during
mitotic arrest, cells predominantly undergo one of two fates governed by alternative
pathways: cell death by apoptosis, or mitotic slippage and survival. To go beyond
this binary description, a better quantitative understanding of these cell responses
is needed.
In this chapter, we propose a quantitative description of the kinetics of colon
carcinoma RKO cell fates in response to the microtubule-targeting agents nocodazole
and taxol, and the spindle-targeting Eg5 inhibitors AZ138 and monastrol. The
mathematical model is calibrated using the in vitro experiments of [151]. Therein,
time-lapse microscopy data demonstrated long and variable durations of mitotic
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arrest in RKO cells prior to subsequent cell death or slippage.
We show that the time-dependent probability cells die in mitosis or slip is
identical for nocodazole, AZ138, and monastrol but significantly different for taxol.
Cell death and slippage responses across drugs can be characterized by Gamma
distributions. We subsequently quantify the hazard rates corresponding to the RKO
cells undergoing death in mitosis and slippage. We demonstrate numerically that
these rates increase with prolonged mitotic arrest.
Additionally, given that the cellular fate is known, the hazard rates are iden-
tical among the different antimitotic drugs. We also demonstrate that RKO cells
display a higher hazard of undergoing death in mitosis than mitotic slippage through-
out the 72-hour experimental time-course. Our model demonstrates that RKO cells
exhibit a triphasic response -first, remain in mitosis, then undergo fast and slow
transition, respectively- dependent on the length of mitotic arrest and irrespective
of cell fate or drug.
This study provides a novel, quantitative perspective on the kinetics behind
the variability in RKO cell drug responses to distinct antimitotic drugs. It represents
the first study of its kind to provide the RKO cellular apoptosis and slippage rates
and their dependency on the length of mitotic arrest.
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5.2 Modeling Approach
5.2.1 Data and Modeling Calibration
In [151], RKO cells in culture were continuously incubated with 0.03 µM AZ138,
0.03 µM AZ138, 100 µM monastrol, 30 ng/mL nocodazole, and 0.1 µM taxol during
a 72-hour imaging period (Figures 5.1(a) - 5.1(e), respectively).
We note that these drug concentrations represent equivalent, minimal satu-
rating dosages of antimitotics required to ensure the efficient induction of mitotic
arrest and a maximal induction of a 4N DNA peak, as analyzed by flow cytometry
and reported in Figure S4B in [151].
Figure 5.1 illustrates cellular fates in response to the prolonged drug exposure.
Specifically, cells can either: (i) successfully divide (black bars), (ii) undergo mitotic
slippage and remain in interphase throughout the duration of the experiment (blue
bars), (iii) die in mitosis (red bars), (iv) undergo division, remain in interphase, then
enter a second mitosis from which they slip and remain in interphase throughout the
duration of the experiment (black, grey, and blue bars), (v) undergo mitotic slippage
then die in interphase (blue and green bars); or (vi) die in interphase without having
entered mitosis (green bars).
The times spent in mitosis (Figure S5A and C in [151], red bars), or in mitosis
following drug addition and before slippage (Figure S5A and C in [151], blue bars)
were subsequently recorded. Therein, “0 min” on the x-axis of the cell fate profiles





Figure 5.1: RKO cell response to (a) 0.03 µM AZ138, (b) 0.03 µM AZ138, (c) 100 µM
monastrol, (d) 30 ng/mL nocodazole, and (e) 0.1 µM taxol during a 72-hour imaging
period. Each horizontal bar represents the fate of a single RKO cell. For each panel
(a)-(e), 100 distinct cell responses are represented.The number of cells corresponding
to each category is shown in bold black.
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(K. Gascoigne, personal communication).
In [151], data were pooled from recordings performed on individual cells syn-
chronized in early S phase, using a thymidine block. Thymidine was added for 16
hours, before cells were released from the block. Drug medium was subsequently
added 4.5 hours later. Imaging using automated time-lapse light microscopy was
started at the same time. Images of RKO cells were then collected every 5 min-
utes for a total duration of 4320 minutes, equivalent to 72 hours (see Figure 1A
in [151] for a timeline of the setup). Therein, mitosis was defined as the cellular
state between nuclear envelope breakdown and the onset of anaphase (Figure S1
in [151]).
In these experimental findings, fewer than 5% of the total number of RKO
cells were reported to have successfully completed mitosis and divided into daugh-
ter cells in response to the microtubule-targeting agents nocodazole and taxol, and
the spindle-targeting Eg5 inhibitors AZ138 and monastrol (see Figure 5.1 for rep-
resentative RKO cell responses). We note that in the absence of any antimitotic
drugs, unsynchronized RKO cells are observed to undergo approximately three mi-
toses during a 72-hour imaging period [156].
Additionally, since in the experimental setup, the cells were spatially sep-
arated, the quantitative live-cell imagining technique employed by [151] reported
individual cell behavior, independent of spatial or global density considerations. As
a result, we did not consider an explicit cellular density or a spatial component in
our mathematical model. Subsequent results reported below are based on the data
reported in Figure 5.1.
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5.2.2 Statistical Tests
We chose to focus on the predominant fates experienced by the RKO cells
under prolonged antimitotic drug exposure, i.e., the fates governed by the death
in mitosis and mitotic slippage pathways. To determine any statistically significant
differences between the different RKO cell responses under prolonged exposure to the
specific antimitotic drugs reported above, we first use the non-parametric Kruskal-
Wallis test (or one-way ANOVA test for ranks) for n = 5 independent samples [218].
These samples correspond to the five RKO populations that undergo death
in mitosis following exposure for a 72-hour period to 0.03 µM AZ138, 1 µM AZ138,
100 µM monastrol, 30 ng/mL nocodazole, and 0.1 µM taxol, respectively. We note
that this test indicates whether the samples tested originate from the same distri-
bution and identifies whether at least one of these samples is statistically significant
(i.e., stochastically dominates). It does not, however, indicate in which sample(s)
this dominance occurs.
We then performed pairwise non-parametric Mann-Whitney tests using all
possible combinations between the groups of cells that died in mitosis (red bars)
or that underwent mitotic slippage (blue bars); n.s., non-significant, *p < 0.05,
**p < 0.01, ***p < 0.005 [219]. We note that this test is a non-parametric test that
assesses whether two independent samples have similarly ranked distributions. It
does not require the assumption of normal distributions.
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5.2.3 Distribution of Times Spent in Mitotic Arrest before Dying or
Slipping out of Mitosis
We use the experimental data to obtain the empirical CDF for the times spent
in mitotic arrest corresponding to the death in mitosis and mitotic slippage pathways
(illustrated in Figure 5.2). This is done by fitting a kernel smoothing function
estimate to the CDF describing the duration of mitotic arrest corresponding to each
drug, describing the duration of mitotic arrest reported in Figure S5A-B in [151].
The procedure is performed using MATLAB’s “ksdensity” function.
This function returns a cumulative density function, based on the sampled
data. The amount of time a cell spends in mitotic arrest is thus assumed to be a
continuous variable. The empirical CDF corresponding to each drug obtained using
the kernel smoothing procedure is illustrated for cells that die in mitosis or slip out
of mitosis in Figures 5.2(b) and 5.2(c), respectively.
Data are adapted from the experimental findings reported in Figure S5A
in [151]. Therein, the RKO cellular fate following prolonged exposure to four dif-
ferent drugs (monastrol, nocodazole, taxol and AZ138) was measured, based on the
duration of drug-induced mitotic arrest. Cell death or slippage responses across
drugs can be characterized by the cell-cycle age “a”-dependent Gamma distribution




Figure 5.2: (a) Statistical differences between the different RKO cell responses
under prolonged exposure to a specific antimitotic drug were analyzed using the non-
parametric Mann-Whitney test; n.s., non-significant, *p < 0.05, **p < 0.01, ***p <
0.001. Pairwise comparisons were performed among all possible combinations between
the groups of cells that died in mitosis (red bars) or that underwent mitotic slippage
(blue bars). The vertical bar plots represents the mean ± s.d. duration of the drug-
induced mitotic arrest in either death in mitosis (red bars) or mitotic slippage (blue
bars). The reported values are in minutes. The number of cells corresponding to
each category is shown in bold black inside each vertical bar plot. The cumulative
distribution functions (CDF) for (c) death in mitosis and (c) mitotic slippage show the




To quantify the transition rates from mitotic arrest to cell death or interphase,
we perform a polynomial least-squares fitting to the empirical transition rate derived
from the Gamma CDF representing the fraction of RKO cells that either died or
slipped after entering mitosis.
The fitting procedure is done using MATLAB’s “polyfit”, “polyval” and “poly-
fix” functions [220]. The first function returns the coefficients for a polynomial of a
user-specified degree, that represents the best fit in the least squares sense for the
input data. The second is used to evaluate the fitted polynomials on a prescribed
set of gridpoints.
It also obtains error estimates in the Root-Mean-Square-Error (RMSE) sense
between the approximate and fitted transitions rates from mitotic arrest to death
in mitosis and mitotic slippage. The third function computes the coefficients for a
polynomial of a user-specified degree, that represents the best fit in the least squares
sense for the input data, with the added constraint that the polynomial must pass
through a user-specified value at a specific point [220].
To best describe the corresponding transition rates from mitosis to death in
mitosis for the non-taxol and taxol drugs, as well as the transition rate from mitosis
to mitotic slippage, we chose to fit piecewise linear polynomials to the empirical
data. Using linear polynomials, as opposed to higher-degree polynomials, enables
us to easily interpret the modeling results into biologically meaningful observations
that could be further tested with more focused experiments.
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5.2.5 Modeling Approach
To study the emerging heterogeneity in RKO cell responses to prolonged an-
timitotic drug exposure, we model the dynamics of the RKO cancer cell population












Herein, the mitotic compartment M(a) is structured by the amount of time
“a” cells spend in mitosis before dying, or slipping out of mitosis into interphase.
The rate of change of M(a) with respect to the experimental time course “a” (i.e.,
cell-cycle age) is represented by d
da
. The derivative d
da
M(a) implies that mitotic cells
advance in cell-cycle age as time progresses.
From mitotic arrest, cells transition with time-dependent rate αMA(a) and
probability p to intrinsic cell death (i.e., apoptosis) or slip out of mitosis into inter-
phase with time-dependent rate αMI(a) and probability 1− p.
In doing so, we implicitly assume that the death in mitosis and mitotic slippage
pathways are simultaneously active, but function independently of each other during
mitotic arrest (i.e., their outcomes are mutually exclusive). This assumption is
supported experimentally by various cancer cell studies [186], and numerically by
predictive modeling in [149]. Additionally, we assume that the amount of time “a”
cells spend in mitotic arrest can be represented as a continuous variable.
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The total number of RKO cells exposed to 0.03 µM AZ138, 1 µM AZ138,
100 µM monastrol, 30 ng/mL nocodazole, and 0.1 µM taxol that undergo either
death in mitosis or mitotic slippage, as depicted in Figure 1A-E, is Mtotal = 86, 85,
92, 85, 98, respectively. Thus, the initial number of RKO cells arrested in mitosis,
corresponding to each drug and cell fate, as evidenced in Figure 5.2 is:
M(0)0.03 µM AZ138 =
43
43
 , M(0)1 µM AZ138 =
85
0




M(0)30 ng/mL nocodazole =
85
0




Thus, Equation (5.2.5) yields a drug-dependent probability p of undergoing




, 1, and 1 in the case of 0.03 µM
AZ138, 1 µM AZ138, monastrol, nocodazole, and taxol, respectively. The solution











In order to determine the hazard functions corresponding to the RKO cells
undergoing death in mitosis and slippage, we estimate the proportion of RKO cells
that survive until time “a” in mitotic arrest and subsequently undergo death in










 ∼ F(a) =
1− FMA(a; k, θ)
1− FMI(a; k, θ)
 , (5.5)
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where the cell death or slippage responses across drugs are characterized by the cell-
cycle age “a”-dependent Gamma CDF FMA(a; k, θ) or FMI(a; k, θ), corresponding to
the death in mitosis and mitotic slippage pathways, respectively. Here, the notation
“∼” represents “is distributed as”.
Each Gamma CDF models the fraction of RKO cells that either die or slip
after entering mitosis as a function of time, and is characterized by its corresponding
shape k and scale parameters θ (see Figures 5.2(b) and 5.2(c) for the quantification).
Herein, F(a) denotes the vector of survival functions corresponding to each pathway,
where the survival function is defined as 1 - CDF.











− ln[1− FMA(a; k, θ)]
− ln[1− FMI(a; k, θ)]
 . (5.6)
























where “∆a” represents the discrete time-step, which is set in our numerical sim-
ulations to one minute. We note that the right-hand side of Equation (5.7) is
equal to
 dda ln[1− FMA(a; k, θ)]
d
da
ln[1− FMI(a; k, θ)]
 , with fMA(a; k, θ) and fMI(a; k, θ) representing
the Gamma probability distribution functions corresponding to the fraction of RKO




5.3.1 The Time-dependent Probability Cells Die in Mitosis or Slip Is
Identical for All Drugs Except for Taxol
To determine whether the type of antimitotic drug used affects the duration
of mitotic arrest in RKO cells, we compare the variable durations of mitotic arrest
illustrated in Figure 5.1 corresponding to cells that either died in mitosis or exited
mitosis and returned to interphase.
We first analyze the statistical differences between the different RKO cell re-
sponses under prolonged exposure to a specific antimitotic drug using the non-
parametric Kruskal-Wallis test for n = 5 independent samples. These correspond
to the five RKO populations that undergo death in mitosis following exposure for a
72-hour period to 0.03 µM AZ138, 1 µM AZ138, 100 µM monastrol, 30 ng/mL noco-
dazole, and 0.1 µM taxol, respectively. The observed aggregate difference among
the five samples was significant beyond the < 0.0001 significance level (data not
shown).
We then performed pairwise non-parametric Mann-Whitney tests using all
possible combinations between the groups of cells that died in mitosis (red bars) or
that underwent mitotic slippage (blue bars); n.s., non-significant, ∗p < 0.05, ∗ ∗ p <
0.01, ∗ ∗ ∗p < 0.005.
RKO cells exposed to taxol exhibit a markedly distinct response to the pro-
longed taxol exposure, i.e., the duration of mitotic arrest induced by taxol in RKO
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(a) (b)
Figure 5.3: Under prolonged (a) 0.03 µM AZ138 and (b) 100 µM monastrol exposure,
RKO cells are more likely to undergo mitotic slippage (blue lines) rather than death
in mitosis (red lines) for a shorter duration of mitotic arrest, i.e., 11.73 and 14.65
hours, respectively.
cells is significantly different compared to the durations of the arrest induced by
nocodazole, monastrol, or AZ138. This effect achieves statistical significance be-
yond the < 0.001 level (Figure 5.2(a)).
5.3.2 Cell Death and Slippage Responses Across Drugs Can Be Char-
acterized by Gamma Distributions
As indicated by our statistical analysis, the time-dependent probability cells
undergo death in mitosis or mitotic slippage is identical for all drugs except for
taxol. To best describe the duration of mitotic arrest cells experience before dying
in mitosis or slipping from mitosis and returning to interphase, we chose to represent
the RKO cell death or slippage responses across drugs by corresponding Gamma
distributions Γ(a; k, θ).
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Each distribution represents the fraction of RKO cells that either died or
slipped after entering mitosis as a function of time (i.e., cell-cycle age “a”), is char-
acterized by its corresponding shape k and scale parameters θ, as illustrated in Fig-
ures 5.2(b) and 5.2(c). The choice of the Gamma distribution to model the duration
of mitotic arrest is motivated by this distribution’s asymmetry and right-skewness,
and is confirmed by the excellent fit to the empirical data.
Specifically, in Figure 5.2(b) the death in mitosis CDF for the non-taxol drugs
can be represented by Γ(5.91, 101.15), with 95% confidence intervals [5, 6.98] and
[85, 120.36] for k and θ, respectively. The RMSE between the empirical CDF (i.e.,
based on the sampled data and obtained by using MATLAB’s “ksdensity” function)
and the Gamma fit is equal to 1.1 · 10−2.
Similarly, the death in mitosis CDF for taxol can be represented by Γ(4.43, 212.9),
with 95% confidence intervals [3.38, 5.8] and [159.9, 283.5] for k and θ, respectively.
The RMSE between the empirical CDF and the Gamma fit is equal to 1.23 · 10−2.
In Figure 5.2(c), the mitotic slippage CDF can be represented by Γ(3.55, 161), with
95% confidence intervals [2.66, 4.72] and [118.4, 218.8] for k and θ, respectively. The
RMSE between the empirical CDF and the Gamma fit is equal to 1.2 · 10−2.
We note that using the Gamma CDF instead of the empirical CDF obtained
by using MATLAB’s “ksdensity” function enables us in subsequent simulations to
obtain a closed-form expression for the age-dependent transition rates from mitosis
to death in mitosis and mitotic slippage, i.e., αMA(a) and αMI(a), respectively, as
demonstrated in Equations (5.5) - (5.7).
118
5.3.3 RKO Cells Are More Likely to Slip in Interphase for Shorter
Durations of Mitotic Arrest, and Die in Mitosis for Longer
Durations of Mitotic Arrest
Under prolonged 0.03 µM AZ138, and 100 µM monastrol exposure, RKO cells
are more likely to undergo mitotic slippage (blue lines in Figures 5.4(a) and 5.4(b))
rather than death in mitosis (red lines in Figures 5.4(a) and 5.4(b)) for a shorter
duration of mitotic arrest, i.e., 11.73 and 14.65 hours, respectively. However, for
durations longer than 11.73 and 14.65 hours of mitotic arrest in RKO cells exposed to
0.03 µM AZ138 and 100 µM monastrol, respectively, cells are more likely to undergo
death in mitosis rather than mitotic slippage.
5.3.4 RKO Cells Exhibit a Triphasic Response Curve Irrespective of
Cell Fate or Antimitotic Drug
From mitotic arrest, cells undergo death in mitosis (i.e., apoptosis) with prob-
ability p and age-dependent transition rate αMA(a). Alternatively, they can undergo
mitotic slippage and return to interphase with probability 1 − p and age-dependent
transition rate αMI(a), as shown in Equation (5.1). We note that these functions
increase with prolonged mitotic arrest, irrespective of cell fate or antimitotic drug,
see Figure 5.4.
We subsequently fit piecewise linear polynomials to the transition rates from





Figure 5.4: The hazard functions corresponding to the RKO cells undergoing death
in mitosis for (a) non-taxol drugs and (b) taxol and to the RKO cells undergoing
mitotic slippage (c) increase monotonically with time, i.e., the duration of mitotic
arrest.
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Figures 5.4(a) and 5.4(b), respectively (red bars), and from mitosis to slippage into
interphase, as illustrated in Figure 5.4(c) (blue bars).
Each labeled “Window” in the Figure 5.4 legends corresponds to time period
during the mitotic arrest RKO cells undergo one of the following: (i) remain in mi-
totic arrest with probability 1 (“Window 1” in Figures 5.4(a) - 5.4(d), respectively),
(ii) fast transition from mitotic arrest to cell death in mitosis, or mitotic slippage
(“Window 2” in Figures 5.4(a) - 5.4(d), respectively), or (iii) slow transition from
mitotic arrest to cell death in mitosis, or mitotic slippage (“Window 3” in Figures
5.4(a) - 5.4(d), respectively).
The hazard functions αMA(a) and αMI(a), corresponding to the death in mi-
tosis induced by non-taxol drugs, taxol (red lines) and mitotic slippage (blue lines),
derived empirically from solving Equation (5.7) are illustrated as the non-linear func-
tions in Figures 5.4(a) - 5.4(c), respectively. In Figure 5.4(d), the distinct hazard
functions corresponding to the death in mitosis responses induced by the non-taxol
drug, taxol, and mitotic slippage responses are plotted, in order to better visualize
and compare RKO cell fate responses across drugs.
The piecewise linear polynomials that best describe the hazard functions cor-




0, for 0′ ≤ a ≤ 82′,
6.28 · 10−6a− 1.96 · 10−5, for 82′ ≤ a ≤ 1164′,





0, for 0′ ≤ a ≤ 86′,
2.2 · 10−6a− 1.89 · 10−4, for 86′ ≤ a ≤ 1416′,




0, for 0′ ≤ a ≤ 4′,
4.89 · 10−6a− ·10−4, for 4′ ≤ a ≤ 907′,
4.29 · 10−7a+ 4 · 10−3, for 907′ ≤ a ≤ 4320′.
(5.10)
The RMSE values between the empirically-derived and fitted αMA(a) and αMI(a)
corresponding to the death in mitosis induced by non-taxol drugs, induced by taxol,
and to mitotic slippage, respectively are 3.27 · 10−4, 1.25 · 10−4, and 2.34 · 10−4,
respectively. The fitted polynomials are illustrated in Figures 5.4(a) - 5.4(c), re-
spectively.
Overall, RKO cells display a higher hazard of undergoing death in mitosis
than mitotic slippage throughout the 72-hour experimental time-course (top red
and blue lines in Figure 5.4(d)). Moreover, the transition from mitotic arrest to cell
death in mitosis for the non-taxol drugs (“Windows 2-3” in Figure 5.4(a)) is overall
faster than the transition from mitotic arrest to mitotic slippage (“Windows 2-3” in
Figure 5.4(c)), with a 1.3 - 1.7-fold difference in the slopes of the piecewise linear
polynomials corresponding to the two alternative pathways.
We additionally note that the taxol-treated RKO cells display the slowest cell
death in mitosis responses across all antimitotic drugs (Figure 5.4(b)), as evidenced
by 1.8 - 2.8-fold difference in the slopes of the piecewise linear polynomials corre-
sponding to the non-taxol drugs and taxol, illustrated in Figure 5.4(d).
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Interestingly, despite taxol being the slowest inducer of cell death in mitosis
in the RKO cell line as evidenced by its specific hazard function (illustrated in
Figure 5.4(d)), this observation is not a good measure for predicting its likelihood
to induce death in mitosis, as 98% of RKO cells exposed to taxol do undergo death
in mitosis following a prolonged mitotic arrest (see Figure 5.1(e) herein and Figure
S5A in [151]). However, this effect might be dose-dependent, as in [151], RKO cells
were only exposed to 0/1 µM taxol during a 72-hour imaging period.
5.4 Discussion of Modeling Results
The mechanisms behind drug-induced prolonged mitotic arrest and cancer cell
death using different antimitotic drugs have only recently begun to be elucidated
using live quantitative cell imaging [148,149,151,154,213].
Using live quantitative single cell imaging, several studies have demonstrated
that individual cancer cells display widely varying responses to antimitotic drugs.
These studies have expanded our understanding of the mechanisms which determine
whether a cell dies in mitosis or survives a prolonged mitotic arrest by returning to
interphase following exposure to antimitotics.
For example, in [151], the authors proposed a model where the two predom-
inant cancer cell fates, i.e., mitotic slippage and death in mitosis, are governed by
two independent networks. The first network involves the cell-cycle regulator cyclin
B1 and its kinase partner Cdk1 as follows: an active anaphase promoting complex
APC/C, an E3 ubiquitin ligase, targets cyclin B1 for proteasome degradation past
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the threshold necessary to maintain sufficient Cdk1 activity and promotes mitotic
exit.
Cells thus escape mitotic arrest without completing mitosis, which can lead to
tetraploidy, senescence, or apoptosis following a subsequent mitosis [137, 189, 221].
The second network involves caspase activation and signal accumulation during
mitotic arrest, the destabilization of the survivin/XIAP complex, and alterations in
the intracellular localization and activation status of Bcl-2 family members [203,215].
Several major questions regarding cancer cell fate and cell response to pro-
longed antimitotic therapies remain unresolved: (1) Does duration of mitotic arrest
predict cell fate? (2) What are the cellular apoptosis and slippage rates corre-
sponding to the death in mitosis and mitotic slippage? (3) Are these rates de-
pendent on the length of mitotic arrest? and finally (4) Do any universal features
in the cellular responses to the different antimitotics characterizing each pathway
exist? [150,151,156,211,222–224].
In this paper, we provide for the first time the cellular apoptosis and slippage
rates and their dependency on the length of mitotic arrest for the death in mitosis
and mitotic slippage pathways in the RKO cell line.
We demonstrate numerically that these rates increase with the duration of mi-
totic arrest. Given the cellular fate is known, they are identical among the distinct
non-taxol antimitotic drugs whose effect on RKO cell fate was investigated in [151].
Importantly, this is a previously unrecognized fact which emerges from our quanti-
tative analysis, i.e., that the proportions of RKO cells that survive until time “a” in
mitotic arrest and subsequently undergo death in mitosis and mitotic slippage are
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identical when cells are exposed to non-taxol drugs.
Moreover, we demonstrate that RKO cells display a higher hazard of under-
going death in mitosis than mitotic slippage throughout the 72-hour experimental
time-course. Additionally, our results indicate that RKO cells exhibit a triphasic
response curve irrespective of cell fate or antimitotic drug. Interestingly, taxol in-
duces the slowest cell death in mitosis responses across all antimitotic drugs in RKO
cells.
However, its slow induction of cell death is not a good measure for predicting
its likelihood to induce death in mitosis, as experimentally, almost all RKO cells
exposed to taxol do undergo death in mitosis following a prolonged mitotic arrest,
as reported in [151,207].
We now briefly comment upon several aspect emerging from our quantitative
modeling results. First, it is intriguing that RKO cells exposed to the microtubule-
destabilizing nocodazole, and Eg5-kinesin inhibitors AZ138 and monastrol exhibit
similar responses to prolonged antimitotic exposure. To the best of our knowledge,
this is a previously unrecognized fact. Our statistical analysis indicates that the
duration of mitotic arrest induced by these drugs is not statistically different between
these drugs, as both cells that die in mitosis or exit mitosis and slip into interphase
display the same CDFs, respectively.
While death in mitosis and slippage kinetics are highly variable from cell to
cell, our results suggests that the microtubule-destabilizing nocodazole and Eg5-
kinesin inhibitors AZ138 and monastrol induce the same duration of mitotic arrest
in RKO cells corresponding to each pathway, despite the different drug targets and
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pharmacokinetics. This highlights a potential functional convergence between the
different non-taxol antimitotic drugs used in the study with respect to inducing
similar distributions of times spent in mitotic arrest before dying or slipping out of
mitosis. This intriguing observation merits further experimental investigation.
However, this effect might be dose-dependent, as in [151], RKO cells were
only exposed to specific antimitotic drug concentrations (i.e., 0.03 µM AZ138, 1 µM
AZ138, 100 µM monastrol, 30 ng/mL nocodazole, and 0.1 µM taxol during a 72-
hour imaging period), and no dose-response experiments were performed. Further
investigations of such dose-response effects are warranted.
Second, RKO cells exposed to taxol exhibit a markedly distinct response to
the prolonged taxol exposure, i.e., the duration of mitotic arrest induced by taxol
in RKO cells is significantly longer compared to the durations of the arrest induced
by nocodazole, monastrol, or AZ138. This effect achieves statistical significance
beyond the ¡ 0.001 level. Our results suggest that taxol is more efficient at inducing
RKO cell death compared to the kinesin-5 inhibitors and nocodazole, but requires a
longer duration of mitotic arrest to induce its proapoptotic effect compared to other
antimitotic drugs, an observation also pointed out in [207].
Third, our results indicate that the fraction of RKO cells that either die or
slip after entering mitosis following continued exposure to nocodazole, monastrol,
AZ138, and taxol can be well-approximated by Gamma distributions. Specifically,
our results indicate that the shape parameter k of the Gamma distributions corre-
sponding to the fraction of RKO cells that die in mitosis under non-taxol and taxol
exposure, or slip back into interphase is 5.91, 4.43, or 3.95, respectively. Interest-
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ingly, these values suggests the existence of approximately six or four independent,
exponentially distributed random variables, each modeling an event responsible for
inducing RKO cell death by the non-taxol drugs, and taxol, respectively.
These events could, for example, be correlated with the activation of executive
caspases, Bcl-xL expression levels, the depletion of the anti-apoptotic protein Mcl-1,
increased microtubule stabilization leading to interference with cellular trafficking
and microtubule-mediated cellular transport, or sequestration of Bax/Bak sufficient
to trigger Mitochondrial Outer Membrane Permeabilization (MOMP).
Additionally, our results also suggest the existence of four independent ex-
ponentially distributed random variables responsible for inducing mitotic slippage
and survival of the RKO cells in interphase. These events could, for example, be
correlated with cyclin B1 level degradation, or the prolonged activation of Cdk1.
Fourth, our results indicate that RKO cells exhibit a triphasic response curve
irrespective of cell fate or antimitotic drug. To the best of our knowledge, this
observation was previously unrecognized. Interestingly, RKO cells remain in mitotic
arrest for periods of time shorter than 1.5 hours, then undergo a fast transition from
arrest to death in mitosis or to mitotic slippage and return in interphase as long as
the duration of mitotic arrest is shorter than 24 hours. If cells continue to remain in
mitotic arrest for more than 24 hours, their subsequent transition to cellular death
or slippage is slower compared to the first phase of transition.
Lastly, our numerical simulations provide quantitative evidence to support
the hypothesis that the duration of mitotic arrest predicts cell fate in RKO cells.
Under prolonged 0.03 µM AZ138 and 100 µM monastrol exposure, RKO cells are
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more likely to undergo mitotic slippage rather than death in mitosis for shorter
durations of mitotic arrest, i.e., 11.73 and 14.65 hours, respectively. One possible
explanation for this observation is that cyclin B1 degradation in RKO cells might
cause cyclin B1 levels to fall below its mitotic exit threshold before the accumulation
of cell death signals sufficient to trigger MOMP.
A short mitotic arrest might thus not allow proapoptotic signals to accumu-
late sufficiently in order to trigger cell death in RKO cells. Conversely, for longer
durations of mitotic arrest, cells are more likely to undergo death in mitosis rather
than mitotic slippage. This suggests that for antimitotic drugs to be able to exert
their proapoptotic effect, exposing cancer cells to antimitotics for prolonged periods
of time and to constant drug concentrations might be more efficient in inducing cell
death than withdrawing the drug after a short exposure. This effect is especially
relevant in taxol-treated RKO cells, as our quantitative modeling results suggest.
In the current work, we provide an in silico modeling framework for studying
the emerging heterogeneity in the response of the colon carcinoma RKO cell line
to antimitotic drugs. Our in silico quantitative approach incorporates experimental
results and uses mathematical models in order to better inform in vitro phenomena.
Our modeling framework will serve as a basis for future studies of cancer cell het-
erogeneity in vitro of more complex responses in the presence of antimitotic drugs of




Ovarian cancer is the most lethal gynecologic malignancy and the 5th lead-
ing cause of death among U.S. women [4]. In addition to optimized surgery and
chemotherapy protocols, significant progress has been made in recent years through
the development of drugs targeting deficiencies in the double-stranded DNA repair
mechanisms, i.e., homologous-recombination repair deficiency (HRD) [225].
For example, PARP inhibitors, such as olaparib or niraparib, have shown
promising activity both in vitro and in vivo as maintenance therapy and as treat-
ment for advanced recurrent platinum-sensitive or resistant ovarian cancers [93]. In
coming years, combination strategies involving PARP inhibitors are likely to bring
further major improvements in the management and treatment of ovarian cancers,
e.g., in combination with the Vascular Endothelial Growth Factor (VEGFR), Ty-
rone Kinase Inhibitor (TKI) cediranib, the angiogenic inhibitor bevacizumab, or the
programmed death-ligand 1 (PD-L1) inhibitor, durvalumab [3,226,227].
This represents an exciting time for the mathematical oncology community
studying ovarian cancer natural history, growth, progression or dynamic response to
treatment in an integrated systems biology/mathematical framework. If accurately
and realistically applied to existing clinical data, such frameworks can complement
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existing clinical results, obtained from large-scale cohort studies or vitro, as these
mathematical experiments can be performed in a relatively inexpensive manner that
relies only on computing power.
Moreover, mathematical models can be used to investigate and highlight po-
tential underlying mechanisms behind the observed experimental data. They pro-
vide an inexpensive framework in which various hypotheses can be tested before
performing time-consuming experiments or awaiting clinical trial results.
In addition, mathematical modeling can potentially identify the most rele-
vant parameters in order to guide the experimental design, and subsequently re-
veal temporal or spatial information related to these parameters. Once a modeling
framework has undergone calibration and validation, it can be used to generate and
predict long-term effects of therapies that would otherwise not be available without
large prospective cohort studies.
In this dissertation we constructed and studied various mathematical modeling
framework aimed at studying the natural history, growth and progression of ovarian
cancers from a population and single-cell level perspective.
First, in Chapter 3, we provided a quantitative mathematical explanation for
why HGSOC detection is not amenable to frequent TVU monitoring, supporting
the clinical findings reported in [101] and results from prospective TVU screening
trials such as the UKTOCS or PLCO.
Next, in Chapter 4, we introduced a mathematical modeling framework of
OVCAR-8 cancer cell dynamics under prolonged antimitotic drug exposure that
incorporates an intrinsic form of heterogeneity via the duration of times cells spend
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in the cell-cycle and apoptosis process. Our work highlighted the fact that the
transient behavior in the cancer cell growth dynamics can signal the emergence and
maintenance of a steady quiescent cell population.
This, in turn, represents a form of intrinsic, non-genetic resistance that results
from variations in cell-cycle parameters [193, 194]. The resulting form of resistance
can potentially decrease the efficacy of therapies that rely on active cell-cycling for
their killing effects, such as traditional chemotherapies [195–197].
Moreover, our result suggest that, unless exposed to saturating drug concen-
trations for prolonged periods of time, cancer cells may not experience a mitotic
arrest for long enough in order to trigger apoptosis, which may have therapeutic
implications as clinical responses depends on apoptosis rates, and not exclusively on
mitotic arrest [137,189].
Lastly, in Chapter 5, we used published single-cell data [151] to study the
kinetics of the death in mitosis and mitotic slippage pathways, responsible for me-
diating the two predominant cancer cell fate responses following prolonged mitotic
arrest. Our modeling results suggest that biochemically distinct antimitotic drugs
can induce functionally similar responses in cancer cells.
Moreover, our study highlights the fact that taxol is more efficient at inducing
cell death compared to other drugs, yet it requires a longer duration of mitotic arrest
to induce its proapoptotic effect, an observation also pointed out in [207].
Several open questions remain unresolved: what are the rates and thresholds
characterizing each network? Why are some cell lines more prone to being apoptosis-
sensitive regardless of the anti-mitotic drug used, but others are more apoptosis-
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resistant and exhibit a diverse range of cell fates during prolonged mitotic arrest?
Future methodological approaches used to address these questions could in-
volve a variety of ODE-PDE models for representing cellular age, as a cell’s progres-
sion through the cell-cycle and mitosis is stalled during mitotic arrest.
Phenotypically structured equations, which arise in population dynamics, could
potentially be used to represent the different cell phenotypes as cells undergo mitotic
arrest. Examples include cells that die in mitosis during the arrest, cells that return
to interphase and die in a subsequent mitosis, cells that return to interphase and
survive, or cells that successfully divide. We leave this for a future work.
This dissertation represents the product of an active collaboration between
mathematicians, clinicians, and experimentalists with the goal of ultimately im-
proving ovarian cancer patient care in the long-term. I strongly believe that in
order to achieve this goal, the design of future mathematical models will have to
closely follow women’s cancers biology, be driven by it, and be closely supported
and informed by clinical and experimental data.
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